WO2017136520A1 - Mitochondrial genome editing and regulation - Google Patents
Mitochondrial genome editing and regulation Download PDFInfo
- Publication number
- WO2017136520A1 WO2017136520A1 PCT/US2017/016168 US2017016168W WO2017136520A1 WO 2017136520 A1 WO2017136520 A1 WO 2017136520A1 US 2017016168 W US2017016168 W US 2017016168W WO 2017136520 A1 WO2017136520 A1 WO 2017136520A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nucleic acid
- cell
- mitochondria
- acid sequence
- guide rna
- Prior art date
Links
- 230000002438 mitochondrial effect Effects 0.000 title claims abstract description 140
- 238000010362 genome editing Methods 0.000 title description 8
- 230000033228 biological regulation Effects 0.000 title description 7
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 275
- 108091033409 CRISPR Proteins 0.000 claims abstract description 172
- 108020005004 Guide RNA Proteins 0.000 claims abstract description 151
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 151
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 151
- 210000003470 mitochondria Anatomy 0.000 claims abstract description 133
- 238000000034 method Methods 0.000 claims abstract description 81
- 210000003527 eukaryotic cell Anatomy 0.000 claims abstract description 59
- 230000014509 gene expression Effects 0.000 claims abstract description 56
- 101710163270 Nuclease Proteins 0.000 claims abstract description 54
- 108020005196 Mitochondrial DNA Proteins 0.000 claims abstract description 42
- 241000702421 Dependoparvovirus Species 0.000 claims abstract description 22
- 210000004027 cell Anatomy 0.000 claims description 161
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 123
- 108091006106 transcriptional activators Proteins 0.000 claims description 46
- 239000013598 vector Substances 0.000 claims description 45
- 108091006107 transcriptional repressors Proteins 0.000 claims description 43
- 230000000295 complement effect Effects 0.000 claims description 32
- 108020004414 DNA Proteins 0.000 claims description 27
- 210000005260 human cell Anatomy 0.000 claims description 17
- 238000001727 in vivo Methods 0.000 claims description 15
- 230000006801 homologous recombination Effects 0.000 claims description 14
- 238000002744 homologous recombination Methods 0.000 claims description 14
- 210000004962 mammalian cell Anatomy 0.000 claims description 12
- 210000005253 yeast cell Anatomy 0.000 claims description 12
- 241000700605 Viruses Species 0.000 claims description 9
- 210000001519 tissue Anatomy 0.000 claims description 6
- 238000010354 CRISPR gene editing Methods 0.000 abstract description 5
- 239000000203 mixture Substances 0.000 abstract description 3
- 108090000623 proteins and genes Proteins 0.000 description 49
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 35
- 230000002103 transcriptional effect Effects 0.000 description 34
- 235000018102 proteins Nutrition 0.000 description 30
- 102000004169 proteins and genes Human genes 0.000 description 30
- 230000035772 mutation Effects 0.000 description 27
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 26
- 239000005090 green fluorescent protein Substances 0.000 description 26
- 239000007924 injection Substances 0.000 description 24
- 101710096438 DNA-binding protein Proteins 0.000 description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
- 230000000694 effects Effects 0.000 description 20
- 230000001105 regulatory effect Effects 0.000 description 20
- 108020004705 Codon Proteins 0.000 description 18
- 201000010099 disease Diseases 0.000 description 17
- 108091006104 gene-regulatory proteins Proteins 0.000 description 16
- 102000034356 gene-regulatory proteins Human genes 0.000 description 16
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 15
- 238000002347 injection Methods 0.000 description 15
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 13
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 13
- 208000009564 MELAS Syndrome Diseases 0.000 description 13
- 230000001627 detrimental effect Effects 0.000 description 13
- 239000002773 nucleotide Substances 0.000 description 13
- 125000003729 nucleotide group Chemical group 0.000 description 13
- 125000006850 spacer group Chemical group 0.000 description 12
- 230000008045 co-localization Effects 0.000 description 11
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 10
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 10
- 230000002950 deficient Effects 0.000 description 10
- 108020004999 messenger RNA Proteins 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- 238000001638 lipofection Methods 0.000 description 9
- 230000008685 targeting Effects 0.000 description 9
- 238000013518 transcription Methods 0.000 description 9
- 230000035897 transcription Effects 0.000 description 9
- 238000010361 transduction Methods 0.000 description 9
- 230000003612 virological effect Effects 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- 241000193996 Streptococcus pyogenes Species 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 229920001184 polypeptide Polymers 0.000 description 8
- 238000010453 CRISPR/Cas method Methods 0.000 description 7
- 108091028113 Trans-activating crRNA Proteins 0.000 description 7
- 208000012268 mitochondrial disease Diseases 0.000 description 7
- 230000026683 transduction Effects 0.000 description 7
- 101100302211 Arabidopsis thaliana RNR2A gene Proteins 0.000 description 6
- 108091079001 CRISPR RNA Proteins 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 101150002896 RNR2 gene Proteins 0.000 description 6
- 108091081024 Start codon Proteins 0.000 description 6
- 241000194020 Streptococcus thermophilus Species 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- 238000012552 review Methods 0.000 description 6
- 241000894007 species Species 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 102100032912 CD44 antigen Human genes 0.000 description 5
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 5
- 241000589602 Francisella tularensis Species 0.000 description 5
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 230000003044 adaptive effect Effects 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000003623 enhancer Substances 0.000 description 5
- 229940118764 francisella tularensis Drugs 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 238000007481 next generation sequencing Methods 0.000 description 5
- 230000006780 non-homologous end joining Effects 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 5
- 102100033647 Activity-regulated cytoskeleton-associated protein Human genes 0.000 description 4
- 241000203069 Archaea Species 0.000 description 4
- 241000701022 Cytomegalovirus Species 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 230000001747 exhibiting effect Effects 0.000 description 4
- 229930182830 galactose Natural products 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000001525 retina Anatomy 0.000 description 4
- 108091032955 Bacterial small RNA Proteins 0.000 description 3
- 238000010356 CRISPR-Cas9 genome editing Methods 0.000 description 3
- 101710177611 DNA polymerase II large subunit Proteins 0.000 description 3
- 101710184669 DNA polymerase II small subunit Proteins 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 201000009906 Meningitis Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000588653 Neisseria Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 102000003661 Ribonuclease III Human genes 0.000 description 3
- 108010057163 Ribonuclease III Proteins 0.000 description 3
- 241000714474 Rous sarcoma virus Species 0.000 description 3
- 241000194017 Streptococcus Species 0.000 description 3
- 241000194019 Streptococcus mutans Species 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 210000004102 animal cell Anatomy 0.000 description 3
- 230000008970 bacterial immunity Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000003412 degenerative effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000007917 intracranial administration Methods 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000003259 recombinant expression Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 101000909256 Caldicellulosiruptor bescii (strain ATCC BAA-1888 / DSM 6725 / Z-1320) DNA polymerase I Proteins 0.000 description 2
- 241000589875 Campylobacter jejuni Species 0.000 description 2
- 101000709520 Chlamydia trachomatis serovar L2 (strain 434/Bu / ATCC VR-902B) Atypical response regulator protein ChxR Proteins 0.000 description 2
- 241000193155 Clostridium botulinum Species 0.000 description 2
- 241001485655 Corynebacterium glutamicum ATCC 13032 Species 0.000 description 2
- 230000007018 DNA scission Effects 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000423296 Gluconacetobacter diazotrophicus PA1 5 Species 0.000 description 2
- 102000005720 Glutathione transferase Human genes 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- 108091060210 Heavy strand Proteins 0.000 description 2
- 101710154606 Hemagglutinin Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 108010015268 Integration Host Factors Proteins 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108091093105 Nuclear DNA Proteins 0.000 description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
- -1 PP7 Proteins 0.000 description 2
- 101710176177 Protein A56 Proteins 0.000 description 2
- 101000902592 Pyrococcus furiosus (strain ATCC 43587 / DSM 3638 / JCM 8422 / Vc1) DNA polymerase Proteins 0.000 description 2
- 230000004570 RNA-binding Effects 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 102000004389 Ribonucleoproteins Human genes 0.000 description 2
- 108010081734 Ribonucleoproteins Proteins 0.000 description 2
- 241001313536 Thermothelomyces thermophila Species 0.000 description 2
- 102100036407 Thioredoxin Human genes 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000004721 adaptive immunity Effects 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 108091005948 blue fluorescent proteins Proteins 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 108010082025 cyan fluorescent protein Proteins 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 239000000185 hemagglutinin Substances 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000008774 maternal effect Effects 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 230000004898 mitochondrial function Effects 0.000 description 2
- 230000036284 oxygen consumption Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 108010079892 phosphoglycerol kinase Proteins 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 238000003153 stable transfection Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 108060008226 thioredoxin Proteins 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 238000003146 transient transfection Methods 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 2
- MNULEGDCPYONBU-WMBHJXFZSA-N (1r,4s,5e,5'r,6'r,7e,10s,11r,12s,14r,15s,16s,18r,19s,20r,21e,25s,26r,27s,29s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-[(2s)-2-hydroxypropyl]-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trio Polymers O([C@@H]1CC[C@@H](/C=C/C=C/C[C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)O[C@H]([C@H]2C)[C@H]1C)CC)[C@]12CC[C@@H](C)[C@@H](C[C@H](C)O)O1 MNULEGDCPYONBU-WMBHJXFZSA-N 0.000 description 1
- MNULEGDCPYONBU-DJRUDOHVSA-N (1s,4r,5z,5'r,6'r,7e,10s,11r,12s,14r,15s,18r,19r,20s,21e,26r,27s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-(2-hydroxypropyl)-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers O([C@H]1CC[C@H](\C=C/C=C/C[C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@H](C)[C@@H](O)C(C)C(=O)[C@H](C)[C@H](O)[C@@H](C)/C=C/C(=O)OC([C@H]2C)C1C)CC)[C@]12CC[C@@H](C)[C@@H](CC(C)O)O1 MNULEGDCPYONBU-DJRUDOHVSA-N 0.000 description 1
- MNULEGDCPYONBU-YNZHUHFTSA-N (4Z,18Z,20Z)-22-ethyl-7,11,14,15-tetrahydroxy-6'-(2-hydroxypropyl)-5',6,8,10,12,14,16,28,29-nonamethylspiro[2,26-dioxabicyclo[23.3.1]nonacosa-4,18,20-triene-27,2'-oxane]-3,9,13-trione Polymers CC1C(C2C)OC(=O)\C=C/C(C)C(O)C(C)C(=O)C(C)C(O)C(C)C(=O)C(C)(O)C(O)C(C)C\C=C/C=C\C(CC)CCC2OC21CCC(C)C(CC(C)O)O2 MNULEGDCPYONBU-YNZHUHFTSA-N 0.000 description 1
- MNULEGDCPYONBU-VVXVDZGXSA-N (5e,5'r,7e,10s,11r,12s,14s,15r,16r,18r,19s,20r,21e,26r,29s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-[(2s)-2-hydroxypropyl]-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers C([C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)OC([C@H]1C)[C@H]2C)\C=C\C=C\C(CC)CCC2OC21CC[C@@H](C)C(C[C@H](C)O)O2 MNULEGDCPYONBU-VVXVDZGXSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 102100025230 2-amino-3-ketobutyrate coenzyme A ligase, mitochondrial Human genes 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- MNULEGDCPYONBU-UHFFFAOYSA-N 4-ethyl-11,12,15,19-tetrahydroxy-6'-(2-hydroxypropyl)-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers CC1C(C2C)OC(=O)C=CC(C)C(O)C(C)C(=O)C(C)C(O)C(C)C(=O)C(C)(O)C(O)C(C)CC=CC=CC(CC)CCC2OC21CCC(C)C(CC(C)O)O2 MNULEGDCPYONBU-UHFFFAOYSA-N 0.000 description 1
- 101150039504 6 gene Proteins 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 241001041760 Acidothermus cellulolyticus 11B Species 0.000 description 1
- 241000417230 Actinobacillus succinogenes 130Z Species 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 108010087522 Aeromonas hydrophilia lipase-acyltransferase Proteins 0.000 description 1
- 241000778935 Akkermansia muciniphila ATCC BAA-835 Species 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 101000651036 Arabidopsis thaliana Galactolipid galactosyltransferase SFR2, chloroplastic Proteins 0.000 description 1
- 241000589941 Azospirillum Species 0.000 description 1
- 241000257169 Bacillus cereus ATCC 10987 Species 0.000 description 1
- 241000606124 Bacteroides fragilis Species 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 241000186020 Bifidobacterium dentium Species 0.000 description 1
- 241001209261 Bifidobacterium longum DJO10A Species 0.000 description 1
- 241000589173 Bradyrhizobium Species 0.000 description 1
- 241001453247 Campylobacter jejuni subsp. doylei Species 0.000 description 1
- 241000941427 Campylobacter lari RM2100 Species 0.000 description 1
- 241001034636 Capnocytophaga ochracea DSM 7271 Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 101710197665 Capsid protein VP2 Proteins 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 241001112695 Clostridiales Species 0.000 description 1
- 241001509423 Clostridium botulinum B Species 0.000 description 1
- 241001509504 Clostridium botulinum F Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 241000186227 Corynebacterium diphtheriae Species 0.000 description 1
- 241001487058 Corynebacterium efficiens YS-314 Species 0.000 description 1
- 241000671338 Corynebacterium glutamicum R Species 0.000 description 1
- 241001525611 Corynebacterium kroppenstedtii DSM 44385 Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 102100039259 Cytochrome c oxidase subunit 8A, mitochondrial Human genes 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 241001082278 Desulfovibrio salexigens DSM 2638 Species 0.000 description 1
- 241000688137 Diaphorobacter Species 0.000 description 1
- 241000933091 Dinoroseobacter shibae DFL 12 = DSM 16493 Species 0.000 description 1
- 241001338691 Elusimicrobium minutum Species 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 241000608038 Fibrobacter succinogenes subsp. succinogenes S85 Species 0.000 description 1
- 241000359186 Finegoldia magna ATCC 29328 Species 0.000 description 1
- 241000382842 Flavobacterium psychrophilum Species 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241001453258 Helicobacter hepaticus Species 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 description 1
- 101001023784 Heteractis crispa GFP-like non-fluorescent chromoprotein Proteins 0.000 description 1
- 101000745956 Homo sapiens Cytochrome c oxidase subunit 8A, mitochondrial Proteins 0.000 description 1
- 206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 101150017040 I gene Proteins 0.000 description 1
- 241001596092 Kribbella flavida DSM 17836 Species 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 241000917009 Lactobacillus rhamnosus GG Species 0.000 description 1
- 241001427851 Lactobacillus salivarius UCC118 Species 0.000 description 1
- 241001193656 Legionella pneumophila str. Paris Species 0.000 description 1
- 241000186805 Listeria innocua Species 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 241001378931 Methanococcus maripaludis C7 Species 0.000 description 1
- 241000825684 Mycobacterium abscessus ATCC 19977 Species 0.000 description 1
- 241000204022 Mycoplasma gallisepticum Species 0.000 description 1
- 241000107400 Mycoplasma mobile 163K Species 0.000 description 1
- 241001135743 Mycoplasma penetrans Species 0.000 description 1
- 241000051161 Mycoplasma synoviae 53 Species 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 241001648684 Nitrobacter hamburgensis X14 Species 0.000 description 1
- 241001037736 Nocardia farcinica IFM 10152 Species 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 241000601272 Parvibaculum lavamentivorans DS-1 Species 0.000 description 1
- 241000606856 Pasteurella multocida Species 0.000 description 1
- 241000981393 Persephonella marina Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000773205 Pseudarthrobacter chlorophenolicus A6 Species 0.000 description 1
- 241000695265 Pseudoalteromonas atlantica T6c Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000647111 Rhodococcus erythropolis PR4 Species 0.000 description 1
- 241001459443 Rhodococcus jostii RHA1 Species 0.000 description 1
- 241001113889 Rhodococcus opacus B4 Species 0.000 description 1
- 241001303434 Rhodopseudomonas palustris BisB18 Species 0.000 description 1
- 241001303431 Rhodopseudomonas palustris BisB5 Species 0.000 description 1
- 241000134686 Rhodospirillum rubrum ATCC 11170 Species 0.000 description 1
- 241000516659 Roseiflexus Species 0.000 description 1
- 241000504328 Roseiflexus castenholzii DSM 13941 Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 241000933177 Shewanella pealeana ATCC 700345 Species 0.000 description 1
- 241001496704 Slackia heliotrinireducens DSM 20476 Species 0.000 description 1
- 241000756832 Streptobacillus moniliformis DSM 12112 Species 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 241001209210 Streptococcus agalactiae A909 Species 0.000 description 1
- 241001540742 Streptococcus agalactiae NEM316 Species 0.000 description 1
- 241000194042 Streptococcus dysgalactiae Species 0.000 description 1
- 241000120569 Streptococcus equi subsp. zooepidemicus Species 0.000 description 1
- 241001167808 Streptococcus gallolyticus UCN34 Species 0.000 description 1
- 241001147754 Streptococcus gordonii str. Challis Species 0.000 description 1
- 241000672607 Streptococcus mutans NN2025 Species 0.000 description 1
- 241000103155 Streptococcus pyogenes MGAS10270 Species 0.000 description 1
- 241000103160 Streptococcus pyogenes MGAS10750 Species 0.000 description 1
- 241000103154 Streptococcus pyogenes MGAS2096 Species 0.000 description 1
- 241001520169 Streptococcus pyogenes MGAS315 Species 0.000 description 1
- 241001148739 Streptococcus pyogenes MGAS5005 Species 0.000 description 1
- 241001332083 Streptococcus pyogenes MGAS6180 Species 0.000 description 1
- 241000103156 Streptococcus pyogenes MGAS9429 Species 0.000 description 1
- 241001496716 Streptococcus pyogenes NZ131 Species 0.000 description 1
- 241001455236 Streptococcus pyogenes SSI-1 Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000192593 Synechocystis sp. PCC 6803 Species 0.000 description 1
- 241001496699 Thermomonospora curvata DSM 43183 Species 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 241000322994 Tolumonas auensis DSM 9187 Species 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 241000999858 Treponema denticola ATCC 35405 Species 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 241000847071 Verminephrobacter eiseniae EF01-2 Species 0.000 description 1
- 108091093126 WHP Posttrascriptional Response Element Proteins 0.000 description 1
- 241000605939 Wolinella succinogenes Species 0.000 description 1
- 241000883281 [Clostridium] cellulolyticum H10 Species 0.000 description 1
- 241000714896 [Eubacterium] rectale ATCC 33656 Species 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 108020001778 catalytic domains Proteins 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 238000011072 cell harvest Methods 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000012350 deep sequencing Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 108010021843 fluorescent protein 583 Proteins 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 244000005702 human microbiome Species 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 229940059406 lactobacillus rhamnosus gg Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229930191479 oligomycin Natural products 0.000 description 1
- MNULEGDCPYONBU-AWJDAWNUSA-N oligomycin A Polymers O([C@H]1CC[C@H](/C=C/C=C/C[C@@H](C)[C@H](O)[C@@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@@H](C)[C@H](O)[C@@H](C)/C=C/C(=O)O[C@@H]([C@@H]2C)[C@@H]1C)CC)[C@@]12CC[C@H](C)[C@H](C[C@@H](C)O)O1 MNULEGDCPYONBU-AWJDAWNUSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940051027 pasteurella multocida Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000013608 rAAV vector Substances 0.000 description 1
- 230000037425 regulation of transcription Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 210000003994 retinal ganglion cell Anatomy 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 229940115920 streptococcus dysgalactiae Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940094937 thioredoxin Drugs 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 108091008023 transcriptional regulators Proteins 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 241001496653 uncultured Termite group 1 bacterium phylotype Rs-D17 Species 0.000 description 1
- 230000009452 underexpressoin Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 239000000277 virosome Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
Definitions
- Mitochondria dysfunction causes various fatal age-related and degenerative disorders. Many of these diseases arise from genetic mutations within the mitochondrial DNA (mtDNA) while others are caused by mutations within the nuclear genome (nDNA) responsible for mitochondrial maintenance. Despite advancements in understanding mitochondrial function, the breadth of pathogenic mtDNA mutations causative of various fatal clinical phenotypes challenge the ability to screen for potential therapeutics. For instance, mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) is a heteroplasmic and maternal inheritance mitochondrial disorder that impairs the brain, nervous, and muscle systems.
- mtDNA mitochondrial DNA
- nDNA nuclear genome
- MELAS stroke-like episodes
- MELAS cases More than 80% of MELAS cases are caused by the A3243G mutation in the tRNA Leu gene, which regulates protein fabrication, oxygen consumption, and energy production.
- mutations responsible for MELAS are known, the lack of knowledge in pathophysiology remains unknown due to the inability to alter patient cell lines and/or generate MELAS mitochondrial disease models. Development of mitochondrial disease models could potentially facilitate drug discovery and disease understanding.
- CRISPR-Cas systems rely on short guide RNAs in complex with Cas proteins to direct degradation of complementary sequences present within invading foreign nucleic acid. See Deltcheva, E. et al. CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. Nature 471, 602-607 (2011); Gasiunas, G, Barrangou,
- CRISPR RNA for adaptive defense and regulation. Annual review of genetics 45, 273-297 (2011).
- CRISPR RNA crRNA fused to a normally trans-encoded tracrRNA
- CRISPR RNA is sufficient to direct Cas9 protein to sequence-specifically cleave target
- one or more mitochondria specific vectors i.e. a vector capable of delivering a nucleic acid sequence into a mitochondria
- a CRISPR system i.e. one or more nucleic acids encoding for a guide RNA and a Cas9 protein and/or alternatively a donor nucleic acid sequence
- the CRISPR system is used to cut or nick the target mitochondrial DNA sequence or otherwise deliver a transcriptional regulator, such as a transcriptional activator or transcriptional repressor, to the target mitochondrial nucleic acid sequence.
- one or more mitochondria specific adeno-associated viruses which include a CRISPR system as described herein are used to deliver the CRISPR system to a target mitochondrial DNA sequence.
- the CRISPR system is used to cut or nick the target mitochondrial DNA sequence or otherwise deliver a transcriptional regulator, such as a transcriptional activator or transcriptional repressor, to the target mitochondrial nucleic acid sequence.
- a method of modulating expression of a target mitochondrial nucleic acid sequence in a mitochondria of a eukaryotic cell including introducing into the mitochondria a first foreign nucleic acid encoding one or more guide RNAs complementary to one or more target mitochondrial nucleic acids, introducing into the mitochondria a second foreign nucleic acid encoding a Cas9 protein, such as a Cas9 enzyme, a Cas9 nickase or a nuclease null Cas9, introducing into the cell a third foreign nucleic acid encoding a transcriptional regulator protein or domain, wherein the one or more guide RNAs, the Cas9 protein, and the transcriptional regulator protein or domain are expressed, wherein the one or more guide RNAs, the Cas9 protein and the transcriptional regulator protein or domain co-localize to the target mitochondrial nucleic acid sequence and wherein the transcriptional regulator protein or domain regulates expression of the target mitochondrial nucleic acid.
- a Cas9 protein such as a Cas9 enzyme
- the foreign nucleic acid encoding the Cas9 protein further encodes the transcriptional regulator protein or domain to create an expression product or fusion of the Cas9 attached to the transcriptional regulator protein or domain.
- the foreign nucleic acid encoding one or more guide RNAs further encodes a target of an RNA-binding domain and the foreign nucleic acid encoding the transcriptional regulator protein or domain further encodes an RNA-binding domain fused to the transcriptional regulator protein or domain.
- the transcriptional regulator protein or domain is a transcriptional activator. According to one aspect, the transcriptional regulator protein or domain upregulates expression of the target mitochondrial nucleic acid. According to one aspect, the transcriptional regulator protein or domain upregulates expression of the target mitochondrial nucleic acid to treat a disease or detrimental condition. According to one aspect, the target mitochondrial nucleic acid is associated with a disease or detrimental condition. According to one aspect, the transcriptional regulator protein or domain is a transcriptional repressor. According to one aspect, the transcriptional regulator protein or domain downregulates expression of the target mitochondrial nucleic acid. According to one aspect, the transcriptional regulator protein or domain downregulates expression of the target mitochondrial nucleic acid to treat a disease or detrimental condition.
- the target nucleic acid is associated with a disease or detrimental condition.
- two or more guide RNAs may be used with a Cas9 nickase wherein the Cas9 nickase co-localizes with the two or more guide RNAs to the target mitochondrial nucleic acid and nicks the target mitochondrial nucleic acid resulting in two or more adjacent nicks.
- the two or more adjacent nicks are on the same strand of the double stranded target mitochondrial nucleic acid.
- the two or more adjacent nicks are on the same strand of the double stranded target mitochondrial nucleic acid and result in homologous recombination. According to one aspect, the two or more adjacent nicks are on different strands of the double stranded target mitochondrial nucleic acid. According to one aspect, the two or more adjacent nicks are on different strands of the double stranded target mitochondrial nucleic acid and create double stranded breaks. According to one aspect, the two or more adjacent nicks are on different strands of the double stranded target mitochondrial nucleic acid and create double stranded breaks resulting in nonhomologous end joining.
- the two or more adjacent nicks are on different strands of the double stranded target mitochondrial nucleic acid and are offset with respect to one another. According to one aspect, the two or more adjacent nicks are on different strands of the double stranded target mitochondrial nucleic acid and are offset with respect to one another and create double stranded breaks. According to one aspect, the two or more adjacent nicks are on different strands of the double stranded target mitochondrial nucleic acid and are offset with respect to one another and create double stranded breaks resulting in nonhomologous end joining.
- the two or more adjacent nicks are on different strands of the double stranded DNA and create double stranded breaks resulting in fragmentation of the target nucleic acid thereby preventing expression of the target nucleic acid.
- the method further includes introducing into the cell a third foreign nucleic acid encoding a donor nucleic acid sequence wherein the two or more nicks results in incorporation of the donor nucleic acid sequence into the target mitochondrial nucleic acid through homologous recombination or nonhomologous end joining.
- a construct that includes a mito-AAV and a nucleic acid encoding a Cas9 protein. According to another aspect, a construct is provided that includes a mito-AAV and a nucleic acid encoding a gRNA. According to one aspect, a construct is provided that includes a mito-AAV, a donor nucleic acid sequence and a nucleic acid sequence encoding a gRNA.
- a eukaryotic cell wherein mitochondria therein include a nucleic acid encoding a guide RNA sequence complementary to a target mitochondrial nucleic acid sequence, a nucleic acid encoding a Cas9 enzyme that interacts with the guide RNA sequence and cleaves the target mitochondrial nucleic acid sequence in a site specific manner, wherein the mitochondria expresses the guide RNA and the Cas9 enzyme, the guide RNA binds to the complementary target nucleic acid and the Cas9 enzyme cleaves the target mitochondrial nucleic acid in a site specific manner.
- a eukaryotic cell wherein mitochondria therein include a guide RNA sequence complementary to a target mitochondrial nucleic acid sequence, a donor nucleic acid sequence, and a Cas9 enzyme that interacts with the guide RNA sequence and cleaves the target mitochondrial nucleic acid sequence in a site specific manner, wherein the guide RNA sequence binds to the complementary target mitochondrial nucleic acid sequence and the Cas9 enzyme cleaves the target mitochondrial nucleic acid sequence in a site specific manner; and wherein the donor sequence is integrated into the mitochondrial nucleic acid sequence.
- a eukaryotic cell wherein mitochondria therein include a guide RNA complementary to the target mitochondrial nucleic acid sequence, a Cas9 protein having inactive nuclease domains, wherein the Cas9 protein having inactive nuclease domains includes a transcriptional activator or repressor domain connected thereto for modulating target mitochondrial nucleic acid expression in vivo, wherein the guide RNA and the Cas9 protein including the transcriptional activator or repressor domain co-localize at the target mitochondrial nucleic acid sequence and wherein the transcriptional activator or repressor domain modulates expression of the target mitochondrial nucleic acid sequence.
- a eukaryotic cell wherein mitochondria therein include a guide RNA complementary to the target mitochondrial nucleic acid sequence, with the guide RNA having a transcriptional activator or repressor domain connected thereto for modulating target mitochondrial nucleic acid expression in vivo, a Cas9 protein having inactive nuclease domains, wherein the guide RNA and the Cas9 protein co-localize at the target mitochondrial nucleic acid sequence and wherein the transcriptional activator or repressor domain modulates expression of the target mitochondrial nucleic acid sequence.
- a eukaryotic cell wherein mitochondria therein include a guide RNA complementary to the target mitochondrial nucleic acid sequence, a Cas9 protein having inactive nuclease domains, a transcriptional activator or repressor domain for modulating target mitochondrial nucleic acid expression in vivo, wherein the transcriptional activator or repressor domain becomes attached to either the guide RNA or the Cas9 protein, wherein the guide RNA and the Cas9 protein co-localize at the target mitochondrial nucleic acid sequence and wherein the transcriptional activator or repressor domain modulates expression of the target mitochondrial nucleic acid sequence.
- Fig. 1A to Fig. IB are directed to targeting mitochondria DNA using an engineered mi to- AAV.
- Fig. 1A is a schematic of rAAV-GFP.
- Fig. IB depicts in schematic the minimal CAG promoter (CAG), the minor or distal heavy-strand promoter (HSP) responsible for mRNA transcription in mitochondria; ATG start codon and ATA mitochondria specific start codon and AGA stop codon and AGG mitochondria specific stop codon. The AGA stop codon and AGG mitochondria specific stop codon were tested to confirm mitochondrial targeting.
- CAG minimal CAG promoter
- HSP minor or distal heavy-strand promoter
- the AGA stop codon and AGG mitochondria specific stop codon were tested to confirm mitochondrial targeting.
- mitochondria specific start codon or/and stop codon constrains the expression of rAAV-GFP specifically in the mitochondria, as evidenced in the colocalization of GFP and mito-tracker signal.
- Fig. 2A to Fig. 2D are directed to genotype and phenotype data confirming mitochondrial genome engineering.
- Fig. 2 A is a schematic design of targeting the 16sRNA of mitochondria genome using mito-AAV-CRISPR system.
- Fig. 2B is a schematic showing co-transduction of mito-AAV-Cas9 with mito-AAV-donor-gRNA virus editing the mtDNA to confer CAP resistance in HT1080 and CAP resistance and MELAS variant in PGP1 iPS cells. Co-transduction of the two components generates a cut (dark triangle).
- the targeting sequence underline
- PAM sequence of Cas9-ST intended T2991C mutation (red) on RNR2 (16sRNA) and A3243G mutation (ref) on TRNL1 coding sequence are illustrated.
- the sequences of Donor DNA and gRNA are provided.
- Figure discloses SEQ ID NOS 10-11, respectively, in order of appearance.
- Fig. 2C depicts data demonstrating that HT1080 mitochondria are engineered with 0.6% homologous recombination (HR) efficiency and iPS cells are engineered with 0.3% HR efficiency. No difference between non-homologous end- joining (NHEJ) repair between positive and negative controls is measured.
- Fig. 3A to Fig. 3B are directed to in vivo mitochondrial genome engineering.
- Fig. 3A is an image of mouse retina imaged using fluorescence microscopy. Green dots indicate transduced retinal cells expressing GFP. The mouse was sacrificed at 50 days after subretinal injections of AAV-CAG-GFP.
- Fig. 3B depicts data derived from GFP+ cells being enriched and sequenced to quantify HR efficiency as measured by deep sequencing. The average HR efficiency of each group is shown and error bars represent standard error from the mean.
- Fig. 4 is a schematic of mito-AAV generation.
- Fig. 5A depicts data directed to viral titer.
- Fig. 5B depicts data directed to infected cells.
- Fig. 6A depicts data directed to homologous recombination efficiency of an engineered T2991C variant.
- Fig. 6B depicts data directed to homologous recombination efficiency of an evolved C2923A variant.
- Embodiments of the present disclosure are directed to methods of targeting mitochondrial nucleic acid for editing or transcriptional regulation.
- one or more vectors are used to introduce one or more nucleic acids encoding a CRISPR system, i.e. a Cas9 protein and a guide RNA, and optionally a donor nucleic acid sequence, into mitochondria of a eukaryotic cell for editing or transcriptional regulation.
- the nucleic acids are expressed and the CRISPR system cuts or nicks the mitochondrial nucleic acid or otherwise delivers a transcriptional regulator to the mitochondrial nucleic acid.
- a vector may include one or more nucleic acids encoding a Cas9 protein, a guide RNA and/or a donor nucleic acid sequence.
- one or more nucleic acids encoding a Cas9 protein, a guide RNA and/or a donor nucleic acid sequence may be present within the same vector or present within different vectors.
- a vector is engineered to specifically target the mitochondria and deliver the one or more nucleic acids encoding a Cas9 protein, a guide RNA and/or a donor nucleic acid sequence into the mitochondria for expression by the mitochondrial DNA.
- an exemplary vector includes a promoter responsible for mRNA transcription in mitochondria, a mitochondria specific start codon and a mitochondria specific stop codon.
- expression of the one or more nucleic acids encoding a Cas9 protein, a guide RNA and/or a donor nucleic acid sequence is limited to expression within the mitochondria.
- an exemplary vector is a mitochondria- specific adeno-associated virus, such as those known in the art.
- a mitochondria-specific adeno-associated virus includes a nucleic acid encoding a Cas9 protein and promoters and codons to express the nucleic acid encoding a Cas9 protein within the mitochondria.
- a mitochondria- specific adeno-associated virus includes a nucleic acid encoding a guide RNA and promoters and codons to express the nucleic acid encoding the guide RNA within the mitochondria.
- a mitochondria-specific adeno-associated virus includes a donor nucleic acid sequence or a nucleic acid encoding a donor nucleic acid sequence to provide the donor nucleic acid sequence within the mitochondria or otherwise Cas9 protein and promoters and codons to express the nucleic acid encoding the donor nucleic acid sequence under operation of a suitable promoter and start and stop codons within the mitochondria.
- a mitochondria- specific adeno-associated virus includes a nucleic acid encoding a Cas9 protein, a nucleic acid encoding a guide RNA and a nucleic acid encoding the donor nucleic sequence and a suitable promoter(s) and start and stop codon(s).
- a mitochondria- specific adeno-associated virus includes a nucleic acid encoding a guide RNA and a nucleic acid encoding the donor nucleic sequence and a suitable promoter(s) and start and stop codon(s).
- RNA guided DNA binding proteins are readily known to those of skill in the art to bind to DNA for various purposes.
- DNA binding proteins may be naturally occurring.
- DNA binding proteins having nuclease activity are known to those of skill in the art, and include naturally occurring DNA binding proteins having nuclease activity, such as Cas9 proteins present, for example, in Type II CRISPR systems.
- Cas9 proteins and Type II CRISPR systems are well documented in the art. See Makarova et al., Nature Reviews, Microbiology, Vol. 9, June 2011, pp. 467-477 including all supplementary information hereby incorporated by reference in its entirety.
- CRISPR-Cas systems rely on short guide RNAs in complex with Cas proteins to direct degradation of complementary sequences present within invading foreign nucleic acid. See Deltcheva, E. et al. CRISPR RNA maturation by trans- encoded small RNA and host factor RNase III. Nature 471, 602-607 (2011); Gasiunas, G., Barrangou, R., Horvath, P. & Siksnys, V. Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proceedings of the National Academy of Sciences of the United States of America 109, E2579-2586 (2012); Jinek, M. et al.
- CRISPR RNA crRNA fused to a normally trans- encoded tracrRNA (“trans-activating CRISPR RNA”) is sufficient to direct Cas9 protein to sequence-specifically cleave target DNA sequences matching the crRNA.
- trans-activating CRISPR RNA a normally trans- encoded tracrRNA fused to a normally trans- encoded tracrRNA
- Cas9 protein to sequence-specifically cleave target DNA sequences matching the crRNA.
- gRNA homologous to a target site results in Cas9 recruitment and degradation of the target DNA. See H. Deveau et al. , Phage response to CRISPR-encoded resistance in Streptococcus thermophilus. Journal of Bacteriology 190, 1390 (Feb, 2008).
- Type II Three classes of CRISPR systems are generally known and are referred to as Type I, Type II or Type III).
- a particular useful enzyme according to the present disclosure to cleave dsDNA is the single effector enzyme, Cas9, common to Type II. See K. S. Makarova et al , Evolution and classification of the CRISPR-Cas systems. Nature reviews. Microbiology 9, 467 (Jun, 2011) hereby incorporated by reference in its entirety.
- the Type II effector system consists of a long pre-crRNA transcribed from the spacer-containing CRISPR locus, the multifunctional Cas9 protein, and a tracrRNA important for gRNA processing.
- the tracrRNAs hybridize to the repeat regions separating the spacers of the pre-crRNA, initiating dsRNA cleavage by endogenous RNase III, which is followed by a second cleavage event within each spacer by Cas9, producing mature crRNAs that remain associated with the tracrRNA and Cas9.
- TracrRNA-crRNA fusions are contemplated for use in the present methods.
- the enzyme of the present disclosure such as Cas9 unwinds the DNA duplex and searches for sequences matching the crRNA to cleave.
- Target recognition occurs upon detection of complementarity between a "protospacer" sequence in the target DNA and the remaining spacer sequence in the crRNA.
- Cas9 cuts the DNA only if a correct protospacer-adjacent motif (PAM) is also present at the 3' end.
- PAM protospacer-adjacent motif
- different protospacer-adjacent motif can be utilized.
- the S. pyogenes system requires an NGG sequence, where N can be any nucleotide.
- S. thermophilus Type II systems require NGGNG (see P. Horvath, R.
- Cas9 In S. pyogenes, Cas9 generates a blunt-ended double- stranded break 3bp upstream of the pro tospacer- adjacent motif (PAM) via a process mediated by two catalytic domains in the protein: an HNH domain that cleaves the complementary strand of the DNA and a RuvC-like domain that cleaves the non-complementary strand.
- PAM pro tospacer- adjacent motif
- the Cas9 protein may be referred by one of skill in the art in the literature as Csnl.
- An exemplary S. pyogenes Cas9 protein sequence is provided in Deltcheva et al., Nature All, 602-607 (2011) hereby incorporated by reference in its entirety.
- Modification to the Cas9 protein is a representative embodiment of the present disclosure.
- CRISPR systems useful in the present disclosure are described in R. Barrangou, P. Horvath, CRISPR: new horizons in phage resistance and strain identification. Annual review of food science and technology 3, 143 (2012) and B. Wiedenheft, S. H. Sternberg, J. A. Doudna, RNA-guided genetic silencing systems in bacteria and archaea. Nature 482, 331 (Feb 16, 2012) each of which are hereby incorporated by reference in their entireties.
- the DNA binding protein is altered or otherwise modified to inactivate the nuclease activity.
- alteration or modification includes altering one or more amino acids to inactivate the nuclease activity or the nuclease domain.
- modification includes removing the polypeptide sequence or polypeptide sequences exhibiting nuclease activity, i.e. the nuclease domain, such that the polypeptide sequence or polypeptide sequences exhibiting nuclease activity, i.e. nuclease domain, are absent from the DNA binding protein.
- Other modifications to inactivate nuclease activity will be readily apparent to one of skill in the art based on the present disclosure.
- a nuclease- null DNA binding protein includes polypeptide sequences modified to inactivate nuclease activity or removal of a polypeptide sequence or sequences to inactivate nuclease activity.
- the nuclease-null DNA binding protein retains the ability to bind to DNA even though the nuclease activity has been inactivated.
- the DNA binding protein includes the polypeptide sequence or sequences required for DNA binding but may lack the one or more or all of the nuclease sequences exhibiting nuclease activity.
- the DNA binding protein includes the polypeptide sequence or sequences required for DNA binding but may have one or more or all of the nuclease sequences exhibiting nuclease activity inactivated.
- a DNA binding protein having two or more nuclease domains may be modified or altered to inactivate all but one of the nuclease domains.
- a DNA binding protein nickase is referred to as a DNA binding protein nickase, to the extent that the DNA binding protein cuts or nicks only one strand of double stranded DNA.
- the DNA binding protein nickase is referred to as an RNA guided DNA binding protein nickase.
- An exemplary DNA binding protein is an RNA guided DNA binding protein nuclease of a Type II CRISPR System, such as a Cas9 protein or modified Cas9 or homolog of Cas9.
- An exemplary DNA binding protein is a Cas9 protein nickase.
- An exemplary DNA binding protein is an RNA guided DNA binding protein of a Type II CRISPR System which lacks nuclease activity.
- An exemplary DNA binding protein is a nuclease-null or nuclease deficient Cas9 protein.
- nuclease-null Cas9 proteins are provided where one or more amino acids in Cas9 are altered or otherwise removed to provide nuclease-null Cas9 proteins.
- the amino acids include D10 and H840. See Jinek et al., Science 337, 816-821 (2012).
- the amino acids include D839 and N863.
- one or more or all of D10, H840, D839 and H863 are substituted with an amino acid which reduces, substantially eliminates or eliminates nuclease activity.
- one or more or all of D10, H840, D839 and H863 are substituted with alanine.
- a Cas9 protein having one or more or all of D10, H840, D839 and H863 substituted with an amino acid which reduces, substantially eliminates or eliminates nuclease activity, such as alanine is referred to as a nuclease-null Cas9 ("Cas9Nuc") and exhibits reduced or eliminated nuclease activity, or nuclease activity is absent or substantially absent within levels of detection.
- nuclease activity for a Cas9Nuc may be undetectable using known assays, i.e. below the level of detection of known assays.
- the Cas9 protein, Cas9 protein nickase or nuclease null Cas9 includes homologs and orthologs thereof which retain the ability of the protein to bind to the DNA and be guided by the RNA.
- the Cas9 protein includes the sequence as set forth for naturally occurring Cas9 from S. thermophiles or S. pyogenes and protein sequences having at least 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98% or 99% homology thereto and being a DNA binding protein, such as an RNA guided DNA binding protein.
- An exemplary CRISPR system includes the S. thermophiles Cas9 nuclease (ST1 Cas9) (see Esvelt KM, et al., Orthogonal Cas9 proteins for RNA-guided gene regulation and editing, Nature Methods., (2013) hereby incorporated by reference in its entirety).
- An exemplary CRISPR system includes the S. pyogenes Cas9 nuclease (Sp. Cas9), an extremely high-affinity (see Sternberg, S.H., Redding, S., Jinek, M., Greene, E.C. & Doudna, J.A. DNA interrogation by the CRISPR RNA-guided endonuclease Cas9.
- nuclease null or nuclease deficient Cas 9 can be used in the methods described herein.
- nuclease null or nuclease deficient Cas9 proteins are described in Gilbert, L.A. et al. CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell 154, 442-451 (2013); Mali, P. et al. CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nature biotechnology 31, 833-838 (2013); Maeder, M.L. et al. CRISPR RNA-guided activation of endogenous human genes. Nature methods 10, 977-979 (2013); and Perez-Pinera, P. et al. RNA-guided gene activation by CRISPR-Cas9-based transcription factors.
- the DNA locus targeted by Cas9 precedes a three nucleotide (nt) 5 NGG-3 ' "PAM” sequence, and matches a 15-22-nt guide or spacer sequence within a Cas9-bound RNA cof actor, referred to herein and in the art as a guide RNA. Altering this guide RNA is sufficient to target Cas9 or a nuclease deficient Cas9 to a target nucleic acid.
- CRISPR-based biotechnology applications see Mali, P., Esvelt, K.M.
- sgRNA single guide RNA
- gRNA and tracrRNA two natural Cas9 RNA cofactors
- the Cas9 protein is an enzymatically active Cas9 protein, a Cas9 protein wild-type protein, a Cas9 protein nickase or a nuclease null or nuclease deficient Cas9 protein.
- Additional exemplary Cas9 proteins include Cas9 proteins attached to, bound to or fused with functional proteins such as transcriptional regulators, such as transcriptional activators or repressors, a Fok-domain, such as Fok 1, an aptamer, a binding protein, PP7, MS2 and the like.
- the Cas9 protein may be delivered directly to a cell by methods known to those of skill in the art, including injection or lipofection, or as translated from its cognate mRNA, or transcribed from its cognate DNA into mRNA (and thereafter translated into protein).
- Cas9 DNA and mRNA may be themselves introduced into cells through electroporation, transient and stable transfection (including lipofection) and viral transduction or other methods known to those of skill in the art.
- Embodiments of the present disclosure are directed to the use of a CRISPR/Cas system and, in particular, a guide RNA which may include one or more of a spacer sequence, a tracr mate sequence and a tracr sequence.
- a guide RNA which may include one or more of a spacer sequence, a tracr mate sequence and a tracr sequence.
- spacer sequence is understood by those of skill in the art and may include any polynucleotide having sufficient complementarity with a target nucleic acid sequence to hybridize with the target nucleic acid sequence and direct sequence-specific binding of a CRISPR complex to the target sequence.
- the guide RNA may be formed from a spacer sequence covalently connected to a tracr mate sequence (which may be referred to as a crRNA) and a separate tracr sequence, wherein the tracr mate sequence is hybridized to a portion of the tracr sequence.
- the tracr mate sequence and the tracr sequence are connected or linked such as by covalent bonds by a linker sequence, which construct may be referred to as a fusion of the tracr mate sequence and the tracr sequence.
- the linker sequence referred to herein is a sequence of nucleotides, referred to herein as a nucleic acid sequence, which connect the tracr mate sequence and the tracr sequence.
- a guide RNA may be a two component species (i.e., separate crRNA and tracr RNA which hybridize together) or a unimolecular species (i.e., a crRNA-tracr RNA fusion, often termed an sgRNA).
- the guide RNA is between about 10 to about 500 nucleotides. According to one aspect, the guide RNA is between about 20 to about 100 nucleotides. According to certain aspects, the spacer sequence is between about 10 and about 500 nucleotides in length. According to certain aspects, the tracr mate sequence is between about 10 and about 500 nucleotides in length. According to certain aspects, the tracr sequence is between about 10 and about 100 nucleotides in length. According to certain aspects, the linker nucleic acid sequence is between about 10 and about 100 nucleotides in length.
- embodiments described herein include guide RNA having a length including the sum of the lengths of a spacer sequence, tracr mate sequence, tracr sequence, and linker sequence (if present). Accordingly, such a guide RNA may be described by its total length which is a sum of its spacer sequence, tracr mate sequence, tracr sequence, and linker sequence (if present). According to this aspect, all of the ranges for the spacer sequence, tracr mate sequence, tracr sequence, and linker sequence (if present) are incorporated herein by reference and need not be repeated.
- a guide RNA as described herein may have a total length based on summing values provided by the ranges described herein. Aspects of the present disclosure are directed to methods of making such guide RNAs as described herein by expressing constructs encoding such guide RNA using promoters and terminators and optionally other genetic elements as described herein.
- the guide RNA may be delivered directly to a cell as a native species by methods known to those of skill in the art, including injection or lipofection, or as transcribed from its cognate DNA, with the cognate DNA introduced into cells through electroporation, transient and stable transfection (including lipofection) and viral transduction.
- donor nucleic acid include a nucleic acid sequence which is to be inserted into mitochondrial DNA according to methods described herein for expression by the mitochondrial DNA.
- the donor nucleic acid sequence may be expressed by the cell.
- the donor nucleic acid is exogenous to the cell. According to one aspect, the donor nucleic acid is foreign to the cell. According to one aspect, the donor nucleic acid is non-naturally occurring within the cell.
- an engineered Cas9-gRNA system which enables RNA-guided mitochondrial DNA regulation in human cells by tethering transcriptional activation domains to either a nuclease-null Cas9 or to guide RNAs.
- one or more transcriptional regulatory proteins or domains are joined or otherwise connected to a nuclease-deficient Cas9 or one or more guide RNA (gRNA).
- the transcriptional regulatory domains correspond to targeted loci.
- aspects of the present disclosure include methods and materials for localizing transcriptional regulatory domains to targeted loci by fusing, connecting or joining such domains to either Cas9N or to the gRNA.
- a Cas9N-fusion protein capable of transcriptional activation.
- a VP64 activation domain (see Zhang et al., Nature Biotechnology 29, 149-153 (2011) hereby incorporated by reference in its entirety) is joined, fused, connected or otherwise tethered to the C terminus of Cas9N.
- the transcriptional regulatory domain is provided to the site of target mitochondrial DNA by the Cas9N protein.
- a Cas9N fused to a transcriptional regulatory domain is provided within a cell along with one or more guide RNAs. The Cas9N with the transcriptional regulatory domain fused thereto bind at or near target mitochondrial DNA.
- the one or more guide RNAs bind at or near target mitochondrial DNA.
- the transcriptional regulatory domain regulates expression of the target mitochondrial nucleic acid sequence.
- a Cas9N-VP64 fusion activated transcription of reporter constructs when combined with gRNAs targeting sequences near the promoter, thereby displaying RNA-guided transcriptional activation.
- a gRNA-fusion protein capable of transcriptional activation is provided.
- a VP64 activation domain is joined, fused, connected or otherwise tethered to the gRNA.
- the transcriptional regulatory domain is provided to the site of target mitochondrial DNA by the gRNA.
- a gRNA fused to a transcriptional regulatory domain is provided within a cell along with a Cas9N protein.
- the Cas9N binds at or near target mitochondrial DNA.
- the one or more guide RNAs with the transcriptional regulatory protein or domain fused thereto bind at or near target mitochondrial DNA.
- the transcriptional regulatory domain regulates expression of the target gene.
- a Cas9N protein and a gRNA fused with a transcriptional regulatory domain activated transcription of reporter constructs, thereby displaying RNA-guided transcriptional activation.
- Transcriptional regulator proteins or domains which are transcriptional activators include VP16 and VP64 and others readily identifiable by those skilled in the art based on the present disclosure.
- TARGET MITOCHONDRIAL NUCLEIC ACID VP16 and VP64 and others readily identifiable by those skilled in the art based on the present disclosure.
- Target mitochondrial nucleic acids include any nucleic acid sequence within mitochondrial DNA to which a co-localization complex as described herein can be useful to either cut, nick or regulate.
- Target nucleic acids include mitochondrial nucleic acid sequences capable of being expressed into proteins.
- mitochondrial DNA such as double stranded mitochondrial DNA, can include the target mitochondrial nucleic acid and a co-localization complex can bind to or otherwise co-localize with the mitochondrial DNA at or adjacent or near the target mitochondrial nucleic acid and in a manner in which the co-localization complex may have a desired effect on the target mitochondrial nucleic acid.
- RNAs and Cas9 proteins which co-localize to a mitochondrial DNA including a target mitochondrial nucleic acid.
- One of skill will further be able to identify transcriptional regulator proteins or domains which likewise co-localize to a mitochondrial DNA including a target mitochondrial nucleic acid.
- Foreign nucleic acids i.e. those which are not part of a cell's natural nucleic acid composition
- Methods include transfection, transduction, viral transduction, microinjection, lipofection, nucleofection, nanoparticle bombardment, transformation, conjugation and the like.
- transfection transduction, viral transduction, microinjection, lipofection, nucleofection, nanoparticle bombardment, transformation, conjugation and the like.
- Cells according to the present disclosure include any cell into which foreign nucleic acids can be introduced and expressed as described herein. It is to be understood that the basic concepts of the present disclosure described herein are not limited by cell type.
- Cells according to the present disclosure include eukaryotic cells, prokaryotic cells, animal cells, plant cells, fungal cells, archael cells, eubacterial cells and the like.
- Cells include eukaryotic cells such as yeast cells, plant cells, and animal cells.
- Particular cells include mammalian cells.
- cells include any in which it would be beneficial or desirable to cut, nick or regulate a target nucleic acid. Such cells may include those which are deficient in expression of a particular protein within the mitochondria leading to a disease or detrimental condition.
- the nucleic acid responsible for expressing the particular protein may be targeted by the methods described herein and a transcriptional activator resulting in upregulation of the target nucleic acid and corresponding expression of the particular protein.
- the methods described herein provide therapeutic treatment.
- Such cells may include those which are over express a particular protein in the mitochondria leading to a disease or detrimental condition.
- diseases or detrimental conditions are readily known to those of skill in the art.
- the nucleic acid responsible for expressing the particular protein may be targeted by the methods described herein and a transcriptional depressor resulting in downregulation of the target nucleic acid and corresponding expression of the particular protein. In this manner, the methods described herein provide therapeutic treatment.
- the cell is a eukaryotic cell.
- the cell is a yeast cell, a plant cell or an animal cell.
- the cell is a mammalian cell.
- the cell is a human cell.
- the cell is a stem cell whether adult or embryonic.
- the cell is a pluripotent stem cell.
- the cell is an induced pluripotent stem cell.
- the cell is a human induced pluripotent stem cell.
- Vectors are contemplated for use with the methods and constructs described herein.
- the term "vector” includes a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked.
- Vectors used to deliver the nucleic acids to cells as described herein include vectors known to those of skill in the art and used for such purposes.
- Certain exemplary vectors may be plasmids, lentiviruses or adeno-associated viruses known to those of skill in the art.
- Vectors include, but are not limited to, nucleic acid molecules that are single- stranded, doublestranded, or partially double-stranded; nucleic acid molecules that comprise one or more free ends, no free ends (e.g.
- vectors refers to a circular double stranded DNA loop into which additional DNA segments can be inserted, such as by standard molecular cloning techniques.
- viral vector wherein virally-derived DNA or RNA sequences are present in the vector for packaging into a virus (e.g. retroviruses, lentiviruses, replication defective retroviruses, adenoviruses, replication defective adenoviruses, and adeno-associated viruses).
- Viral vectors also include polynucleotides carried by a virus for transfection into a host cell.
- Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g. bacterial vectors having a bacterial origin of replication and episomal mammalian vectors).
- Other vectors e.g., non-episomal mammalian vectors
- certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as "expression vectors.”
- Common expression vectors of utility in recombinant DNA techniques are often in the form of plasmids.
- Recombinant expression vectors can comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory elements, which may be selected on the basis of the host cells to be used for expression, that is operatively-linked to the nucleic acid sequence to be expressed.
- "operably linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory element(s) in a manner that allows for expression of the nucleotide sequence (e.g. in an in vitro transcription/translation system or in a host cell when the vector is introduced into the host cell).
- Methods of non-viral delivery of nucleic acids or native DNA binding protein, native guide RNA or other native species include lipofection, microinjection, biolistics, virosomes, liposomes, immunoliposomes, polycation or lipid:nucleic acid conjugates, naked DNA, artificial virions, and agent-enhanced uptake of DNA.
- Lipofection is described in e.g., U.S. Pat. Nos. 5,049,386, 4,946,787; and 4,897,355) and lipofection reagents are sold commercially (e.g., TransfectamTM and LipofectinTM).
- Cationic and neutral lipids that are suitable for efficient receptor-recognition lipofection of polynucleotides include those of Feigner, WO 91/17424; WO 91/16024. Delivery can be to cells (e.g. in vitro or ex vivo administration) or target tissues (e.g. in vivo administration).
- the term native includes the protein, enzyme or guide RNA species itself and not the nucleic acid encoding the species.
- the vectors are engineered to specifically target to mitochondria and/or codon optimized for mitochondrial specific delivery of the nucleic acid sequences within the vectors.
- regulatory element is intended to include promoters, enhancers, internal ribosomal entry sites (IRES), and other expression control elements (e.g. transcription termination signals, such as polyadenylation signals and poly-U sequences).
- promoters e.g. promoters, enhancers, internal ribosomal entry sites (IRES), and other expression control elements (e.g. transcription termination signals, such as polyadenylation signals and poly-U sequences).
- ITR internal ribosomal entry sites
- regulatory elements e.g. transcription termination signals, such as polyadenylation signals and poly-U sequences.
- Regulatory elements include those that direct constitutive expression of a nucleotide sequence in many types of host cell and those that direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences).
- a tissue-specific promoter may direct expression primarily in a desired tissue of interest, such as muscle, neuron, bone, skin, blood, specific organs (e.g. liver, pancreas), or particular cell types (e.g. lymphocytes). Regulatory elements may also direct expression in a temporal- dependent manner, such as in a cell-cycle dependent or developmental stage-dependent manner, which may or may not also be tissue or cell-type specific.
- a vector may comprise one or more pol III promoter (e.g. 1, 2, 3, 4, 5, or more pol III promoters), one or more pol II promoters (e.g. 1, 2, 3, 4, 5, or more pol II promoters), one or more pol I promoters (e.g.
- pol III promoters include, but are not limited to, U6 and HI promoters.
- pol II promoters include, but are not limited to, the retroviral Rous sarcoma virus (RSV) LTR promoter (optionally with the RSV enhancer), the cytomegalovirus (CMV) promoter (optionally with the CMV enhancer) [see, e.g., Boshart et al, Cell, 41:521-530 (1985)], the SV40 promoter, the dihydrofolate reductase promoter, the ⁇ -actin promoter, the phosphoglycerol kinase (PGK) promoter, and the EFla promoter and Pol II promoters described herein.
- RSV Rous sarcoma virus
- CMV cytomegalovirus
- PGK phosphoglycerol kinase
- enhancer elements such as WPRE; CMV enhancers; the R-U5' segment in LTR of HTLV-I (Mol. Cell. Biol., Vol. 8(1), p. 466-472, 1988); SV40 enhancer; and the intron sequence between exons 2 and 3 of rabbit ⁇ -globin (Proc. Natl. Acad. Sci. USA., Vol. 78(3), p. 1527-31, 1981).
- WPRE WPRE
- CMV enhancers the R-U5' segment in LTR of HTLV-I
- SV40 enhancer SV40 enhancer
- the intron sequence between exons 2 and 3 of rabbit ⁇ -globin Proc. Natl. Acad. Sci. USA., Vol. 78(3), p. 1527-31, 1981.
- a vector can be introduced into host cells to thereby produce transcripts, proteins, or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (e.g., clustered regularly interspersed short palindromic repeats (CRISPR) transcripts, proteins, enzymes, mutant forms thereof, fusion proteins thereof, etc.).
- CRISPR clustered regularly interspersed short palindromic repeats
- a terminator sequence includes a section of nucleic acid sequence that marks the end of a gene or operon in genomic DNA during transcription. This sequence mediates transcriptional termination by providing signals in the newly synthesized mRNA that trigger processes which release the mRNA from the transcriptional complex. These processes include the direct interaction of the mRNA secondary structure with the complex and/or the indirect activities of recruited termination factors. Release of the transcriptional complex frees RNA polymerase and related transcriptional machinery to begin transcription of new mRNAs. Terminator sequences include those known in the art and identified and described herein.
- epitope tags include histidine (His) tags, V5 tags, FLAG tags, influenza hemagglutinin (HA) tags, Myc tags, VSV-G tags, and thioredoxin (Trx) tags.
- reporter genes include, but are not limited to, glutathione-S- transferase (GST), horseradish peroxidase (HRP), chloramphenicol acetyltransferase (CAT) beta-galactosidase, betaglucuronidase, luciferase, green fluorescent protein (GFP), HcRed, DsRed, cyan fluorescent protein (CFP), yellow fluorescent protein (YFP), and autofluorescent proteins including blue fluorescent protein (BFP).
- GST glutathione-S- transferase
- HRP horseradish peroxidase
- CAT chloramphenicol acetyltransferase
- beta-galactosidase beta-galactosidase
- betaglucuronidase beta-galactosidase
- luciferase green fluorescent protein
- GFP green fluorescent protein
- HcRed HcRed
- DsRed cyan fluorescent protein
- YFP yellow fluorescent protein
- Embodiments of the present disclosure are directed to a method of delivering a Cas9 protein to cells within a subject comprising administering to the subject, such as systemically administering to the subject, such as by intravenous administration or injection, intraperitoneal administration or injection, intramuscular administration or injection, intracranial administration or injection, intraocular administration or injection, subcutaneous administration or injection, a Cas9 protein or a nucleic acid encoding the Cas9 protein.
- Embodiments of the present disclosure are directed to a method of delivering a guide RNA having an RNA domain (selected RNA sequence) attached thereto to cells within a subject comprising administering to the subject, such as systemically administering to the subject, such as by intravenous administration or injection, intraperitoneal administration or injection, intramuscular administration or injection, intracranial administration or injection, intraocular administration or injection, subcutaneous administration or injection, a guide RNA or a nucleic acid encoding the guide RNA.
- administering to the subject such as systemically administering to the subject, such as by intravenous administration or injection, intraperitoneal administration or injection, intramuscular administration or injection, intracranial administration or injection, intraocular administration or injection, subcutaneous administration or injection, a guide RNA or a nucleic acid encoding the guide RNA.
- Embodiments of the present disclosure are directed to a method of delivering a Cas9 protein and a guide RNA to cells within a subject comprising administering to the subject, such as systemically administering to the subject, such as by intravenous administration or injection, intraperitoneal administration or injection, intramuscular administration or injection, intracranial administration or injection, intraocular administration or injection, subcutaneous administration or injection, a Cas9 protein or a nucleic acid encoding the Cas9 protein and a guide RNA or a nucleic acid encoding the guide RNA.
- Mitochondrial mutations trigger various degenerative disorder, cancer, and aging. Mitochondria dysfunction causes various fatal age-related and degenerative disorders. See D. C. Wallace, Mitochondrial diseases in man and mouse. Science 283, 1482-1488 (1999); F. Terasaki, M. Tanaka, K. Kawamura, Y. Kanzaki, M. Okabe, T. Hayashi, H. Shimomura, T. Ito, M. Suwa, J. S. Gong, J. Zhang, Y.
- Kitaura A case of cardiomyopathy showing progression from the hypertrophic to the dilated form: association of Mt8348A— >G mutation in the mitochondrial tRNA(Lys) gene with severe ultrastructural alterations of mitochondria in cardiomyocytes. Jpn Circ J 65, 691-694 (2001); G. M. Martin, L. A. Loeb, Ageing: mice and mitochondria. Nature 429, 357-359 (2004); S. G. Jarrett, A. S. Lewin, M. E. Boulton, The importance of mitochondria in age-related and inherited eye disorders. Ophthalmic research 44, 179-190 (2010); O. Z. Karicheva, O. A. Kolesnikova, T. Schirtz, M. Y.
- mitochondrial encephalomyopathy lactic acidosis, and stroke-like episodes (MELAS) is a heteroplasmic and maternal inheritance mitochondrial disorder that impairs the brain, nervous, and muscle systems. More than 80% of MELAS cases are caused by the A3243G mutation in the tRNA Leu gene, which regulates protein fabrication, oxygen consumption, and energy production.
- Diseases and detrimental conditions may be characterized by abnormal loss of expression or underexpression of a particular protein or abnormal gain or overexpression of a particular protein. Such diseases or detrimental conditions can be treated by upregulation or down regulation of the particular protein. Accordingly, methods of treating a disease or detrimental condition are provided where the co-localization complex as described herein associates or otherwise binds to mitochondrial DNA including a target mitochondrial nucleic acid, and the transcriptional activator of the co-localization complex upregulates expression of the target nucleic acid or the transcriptional repressor of the co-localization complex downregulates expression of the target nucleic acid.
- the co-localization complex as described herein associates or otherwise binds to mitochondrial DNA including a target mitochondrial nucleic acid, and the transcriptional activator of the co-localization complex upregulates expression of the target nucleic acid or the transcriptional repressor of the co-localization complex downregulates expression of the target nucleic acid.
- mitochondrial DNA Mutations in mitochondrial DNA are known to result in alteration and pathological development in mitochondrial function and mitochondrial diseases, as well as cancer, diabetes, cardiovascular diseases, neurodegenerative disorders and aging (See, Alexeyev M. et al., The Maintenance of Mitochondrial DNA Integrity— Critical Analysis and Update, Cold Spring Harb Perspect Biol, (2013); 5:a012641).
- methods of treating a disease or detrimental condition are provided where foreign DNA is integrated into a mitochondrial nucleic acid sequence of a eukaryotic cell via providing to the mitochondria a guide RNA sequence complementary to a target mitochondrial nucleic acid sequence, providing to the mitochondria a donor sequence, providing to the mitochondrial a Cas9 enzyme that interacts with the guide RNA sequence and cleaves the target mitochondrial nucleic acid sequence in a site specific manner, wherein the guide RNA sequence binds to the complementary target mitochondrial nucleic acid sequence and the Cas9 enzyme cleaves the target mitochondrial nucleic acid sequence in a site specific manner; and wherein the donor sequence is integrated into the mitochondrial nucleic acid sequence.
- HT 1080 cells were initially grown and maintained in Dulbecco's modified Eagle's medium (DMEM, Invitrogen) high glucose supplemented with 10% fetal bovine serum (Invitrogen), penicillin/streptomycin (pen/strep, Invitrogen) and nonessential amino acids (Invitrogen).
- DMEM Dulbecco's modified Eagle's medium
- pen/strep penicillin/streptomycin
- nonessential amino acids Invitrogen
- the HT1080 cell lines were maintained in Dulbecco's modified eagle medium with no glucose supplemented with 10 mM galactose, 10% fetal bovine serum (Invitrogen), penicillin/streptomycin (pen/strep, Invitrogen), nonessential amino acids (Invitrogen), 5 mM sodium pyruvate (Invitrogen), and 5 mM HEPES (Invitrogen).
- the PGP1 iPS cells were grown and maintained in mTeSRl basal medium (mTeSRl, Stemcell Technologies) with IX mTeSRl Supplement and penicillin/streptomycin (pen/strep, Invitrogen).
- AAV-CAG-GFP (7.4 x 10 11 GC/mL) and mito-AAV-HSP-GFP (3 x 10 11 GC/mL) were produced and were used to infect HT1080 seeded at 200,000 cells in a 12 well plate at 2.0 x 10 10 genome copies respectively. After 3 days post virus transduction, the number of infected HT1080 cells was visualized using optical fluorescence microscopy and quantified by flow cytometry.
- a mito-AAV-Cas9 and mito-AAV-donor-RNR2 T2991c -gRNA were constructed and co-transduced to target and modify the RNR2 (16sRNA) gene with a T2991C mutation.
- HT1080 cells transduced with mito-AAV-Cas9 and HT1080 wild type served as negative controls.
- the infected cells were cultured for 7 days under normal conditions to allow the mito-AAVs to dilute out of the cells (Day 0).
- the infected cells were harvested and plated at 15,000 cells per 9.5 cm 2 (1 well of a 6 well plate) and cultured in triplicates of 0, 150, 300 and 500 ⁇ g/mL CAP and harvested after 7 days.
- a mito-AAV-Cas9 and mito-AAV-donor-RNR2 T2991c - TRNLl A3243G -gRNA were co- transduced into PGP1 iPS cells to target and modify both the RNR2 (16sRNA) gene with a T2991C mutation and the TRNLl (tRNA Leu ) gene with the A3243G mutation to create a selectable and programmable cell line to potentially model MELAS.
- HT1080 cells and HT1080 transduced with only mito-AAV-Cas9 ('Negative') cells were then seeded at 80,000 cells per 9.5 cm 2 and cultured in galactose (or glucose free) media spiked with 250 ⁇ g/mL CAP.
- galactose or glucose free
- Oligomycin induces a decrease in the cellular content of a pathogenic mutation in the human mitochondrial ATPase 6 gene. / Biol Chem 274, 9386-9391 (1999); and B. H.
- Cells were rinsed with PBS, trypsinized, and harvested by centrifuging at 1000 x g for 4 minutes.
- Genomic mtDNA was extracted using prepGEM (Zygem); targeted amplification of engineered mtDNA were amplified using specially designed illumine adaptor primers and prepared for NGS through PCR and analyzed according to L. Yang, M. Guell, S. Byrne, J. L. Yang, A. De Los Angeles, P. Mali, J. Aach, C. Kim-Kiselak, A. W. Briggs, X. Rios, P. Y. Huang, G. Daley, G. Church, Optimization of scarless human stem cell genome editing. Nucleic Acids Res 41, 9049-9061 (2013) hereby incorporated by refernece in its entirety.
- Transduced HT1080 cells that cultured in triplicates of 0, 150, 300 and 500 ⁇ g/mL CAP and harvested after 7 days (Fig. 2B) were harvested and checked for viability using trypan blue solution, 0.4% (Life Technologies). In vivo Retina Studies
- Neonatal CD-I mice (Charles River Laboratories) were used for all injections. All animal experiments in this study were approved by the Institutional Animal Care and Use Committee at Harvard University. Subretinal viral injections were performed on male and female pups using a Femtojet Express pressure injector (Eppendorf; 920010521) and glass micropipets (Origio; C060609). For experiments where GFP was analyzed using anti-GFP immunohistochemistry, -0.1 ⁇ of AAV (7xlO n GC/ml) was used, and for the FACS sorting -0.1 ⁇ of AAV (2xl0 13 GC/ml) was used. Animals were sacrificed at p20-pl20. For the FACS sorting experiments, retinae were enzymatically dissociated with a papain mix, and gentle pipetting.
- mouse eyeballs were fixed for 2 h in 4% PFA in PBS (pH 7.4). Retinae were then dissected out in PBS, and washed 3x in PBS for 10 minutes each. Whole retinae were blocked for 1 hour in 0.3% Triton, 0.02% SDS, 1% BSA in PBS. Samples were then incubated in primary antibody (Rabbit anti-GFP, Invitrogen, A6455, 1:500) overnight at 4°C. Next day, retinae were washed three times in lx PBS and incubated for 3 h with donkey anti- rabbit Cy3 fluorescently coupled secondary antibody (1:250). Slides were washed three times with lx PBS 15 min each, where the last wash contained DAPI (Invitrogen, D1306). Finally, retinae were mounted using Fluoromount-G (Southern Biotech, 0100-01)
- Engineered mt-AAV Four constructs as shown in Fig. 4 were made as described above and were used to generate engineered mito-AAV: pVPl,3 and pVP2A-MTS encoding the capsid proteins, rAAV-vector with selected transgene, and pAdDeltaF6 containing auxiliary proteins. See H. Yu, R. D. Koilkonda, T. H. Chou, V. Porciatti, S. S. Ozdemir, V. Chiodo, S. L. Boye, S. E. Boye, W. W. Hauswirth, A. S. Lewin, J.
- the viral capsid protein VP2 was first engineered by fusing it with a mitochondrial targeting sequence (MTS) of the COX8 (mito-AAV) according to Proc Natl Acad Sci U S A 109, E1238-1247 (2012).
- MTS mitochondrial targeting sequence
- rAAV-GFP five versions of rAAV-GFP were generated varying the promoters as well as the protein codon of GFP (See Fig. 1A): 1) minimal CAG promoter (CAG); 2) the minor or distal heavy- strand promoter (HSP) responsible for mRNA transcription in mitochondria; 3) HSP promoter with ATA mitochondria specific start codon; 4) HSP with AGA stop codon; and 5) HSP with AGG mitochondria specific stop codon.
- mitochondria specific start codon and/or stop codon constrain(s) the expression of rAAV-GFP specifically to the mitochondria, evidenced as the colocalization of GFP and mito-tracker signal.
- Fig. IB See also Fig. 5A and 5B which provide data relating to viral titer and infectionality of CAG- GFP, WT ("CAG-GFP-WT”); HSP-GFP, VP1,3, VP2-MTS ("HSP-GFP-V2-MTS”); HSP- Cas9-ST, VP1,3, VP2-MTS (“HSP-STl-MTS”); and Donor-gRNA, VP2-MTS "(Donor- Mutation-U6-TargetGene-MTS”) AVV vectors in HT1080 cells.
- Fig. 5A shows that titer yield, which was quantified by QuickTiterTM AAV Quantitation Kit (Cell Biolabs), was not affected by packaging contents. Each virus was transduced at 2 x 1010 genome copies into HT1080 cells. As shown in Fig. 5B, flow cytometry was used to quantify number of HT1080 cells infected to compare the infectionality of engineered viral particle V.S. wild type CAG- GFP-WT. Neg refers to wild-type HT1080 cells.
- Mitochondrial DNA variants C2939A or T2991C are known to confer CAP resistance. See N. Howell, I. Kubacka, Sequence analysis of mitochondrial chloramphenicol resistance mutations in Chinese hamster cells. Mammalian genome : official journal of the International Mammalian Genome Society 4, 271-275 (1993) hereby incorporated by reference in its entirety. CAP resistant cell lines were engineered by introducing specific mutations in the mitochondria genome. A mito-AAV-Cas9 and mito-AAV-donor- RNR2 T2991c -gRNA were constructed and co-transduced to target and modify the RNR2 (16sRNA) gene with a T2991C mutation. See Fig. 2A, 2B, and Fig.
- HT1080 cells transduced with mito-AAV-Cas9 and HT1080 wild-type served as negative controls.
- the infected cells were cultured for 7 days under normal conditions to allow the mito-AAVs to dilute out of the cells (Day 0).
- the infected cells were cultured in 0, 150, 300 and 500 ⁇ g/mL CAP and harvested after 7 days.
- NGS results confirmed introduction of the T2991C variant in HT1080 cells with 0.6 % homologous recombination (HR) efficiency (or 25 fold compared to HT1080 cells infected with only mito-AAV-Cas9). See Fig. 2C.
- Fig. 6 A and 6B are directed to chloramphenicol selection for engineered mitochondria which suggests a need for an optimized method to enrich for mitochondrial genome engineering in vitro.
- HT1080 cells were cultured in 250 ⁇ g/mL CAP galactose (glucose-free) media over 21 days to enrich for engineered T2991C mutation (green diamond).
- a programmable cell line to model MELAS was created using the methods described herein.
- a mito-AAV-Cas9 and a mito-AAV-donor-RNR2 T2991c - TRNL1 A3243G - gRNA were co-transduced into PGP1 iPS cells to target and modify both the RNR2 (16sRNA) gene with a T2991C mutation and the TRNL1 (tRNA Leu ) gene with the A3243G mutation.
- This system was quantified at 0.3 % efficiency HR targeting efficiency of transduced cell lines (14X compared to iPSCs transduced with only mito-AAV-Cas9). See Fig. 2C.
- MELAS has been known to affect the retinal ganglion cells. Methods described herein were used to edit the mitochondrial genome of the retina in vivo. Mito-AAV-CRISPR systems were engineered to introduce the A2601G on mtDNA tRNA Leu , which aligns to the human A3243G variant. Mito-AAV-Cas9 and mito-AAV-donor-gRNA were co-injected into the mouse eye subretinally, along with mito-AAV-CAG-GFP to track the transduction. Retinas were dissociated and GFP positive cells were enriched and prepared for NGS to quantify the editing efficiency on the targeting site (see Fig. 3A). Notably, the efficiency of editing in vivo mitochondria was about 7% compared to 0% in the negative controls. The in vivo efficiency using infection by AAV is 10 fold higher than the efficiency observed with in vitro models (see Fig. 3B).
- Illumina adapter primers used for sequencing are provided below.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Immunology (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Methods and compositions of altering mitochondrial DNA of a eukaryotic cell are provided using one or more of a mitochondrial specific adeno-associated virus to deliver one or more nucleic acids encoding CRISPR system including a Cas9 protein or its nuclease inactive variant and a guide RNA into a mitochondria for expression within the mitochondria. The Cas9 system can cut, nick or regulate a target mitochondrial nucleic acid.
Description
MITOCHONDRIAL GENOME EDITING AND REGULATION
RELATED APPLICATION DATA
This application claims priority to U.S. Provisional Application No. 62/291,040 filed on February 4, 2016 which is hereby incorporated herein by reference in its entirety for all purposes.
STATEMENT OF GOVERNMENT INTERESTS
This invention was made with government support under Grant No. P50 HG005550 from the National Institutes of Health. The government has certain rights in the invention.
SEQUENCE LISTING
The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on February 2, 2017, is named 010498.00903_WO_SL.txt and is 17,316 bytes in size.
BACKGROUND
Mitochondria dysfunction causes various fatal age-related and degenerative disorders. Many of these diseases arise from genetic mutations within the mitochondrial DNA (mtDNA) while others are caused by mutations within the nuclear genome (nDNA) responsible for mitochondrial maintenance. Despite advancements in understanding mitochondrial function, the breadth of pathogenic mtDNA mutations causative of various fatal clinical phenotypes challenge the ability to screen for potential therapeutics. For instance, mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) is a heteroplasmic and maternal inheritance mitochondrial disorder that impairs the brain, nervous, and muscle
systems. More than 80% of MELAS cases are caused by the A3243G mutation in the tRNALeu gene, which regulates protein fabrication, oxygen consumption, and energy production. Although mutations responsible for MELAS are known, the lack of knowledge in pathophysiology remains unknown due to the inability to alter patient cell lines and/or generate MELAS mitochondrial disease models. Development of mitochondrial disease models could potentially facilitate drug discovery and disease understanding.
Bacterial and archaeal CRISPR-Cas systems rely on short guide RNAs in complex with Cas proteins to direct degradation of complementary sequences present within invading foreign nucleic acid. See Deltcheva, E. et al. CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. Nature 471, 602-607 (2011); Gasiunas, G, Barrangou,
R., Horvath, R & Siksnys, V. Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proceedings of the National Academy of Sciences of the United States of America 109, E2579-2586 (2012); Jinek, M. et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816-821
(2012); Sapranauskas, R. et al. The Streptococcus thermophilus CRISPR/Cas system provides immunity in Escherichia coli. Nucleic acids research 39, 9275-9282 (2011); and Bhaya, D.,
Davison, M. & Barrangou, R. CRISPR-Cas systems in bacteria and archaea: versatile small
RNAs for adaptive defense and regulation. Annual review of genetics 45, 273-297 (2011). A recent in vitro reconstitution of the S. pyogenes type II CRISPR system demonstrated that crRNA ("CRISPR RNA") fused to a normally trans-encoded tracrRNA ("trans-activating
CRISPR RNA") is sufficient to direct Cas9 protein to sequence-specifically cleave target
DNA sequences matching the crRNA. Expressing a gRNA homologous to a target site results in Cas9 recruitment and degradation of the target DNA. See H. Deveau et al. , Phage response to CRISPR-encoded resistance in Streptococcus thermophilus. Journal of
SUMMARY
Aspects of the present disclosure are directed to a method of altering mitochondrial DNA using a Cas9 protein and a guide RNA which form a complex with a target mitochondrial nucleic acid sequence. According to one aspect, one or more mitochondria specific vectors, i.e. a vector capable of delivering a nucleic acid sequence into a mitochondria, include a CRISPR system, i.e. one or more nucleic acids encoding for a guide RNA and a Cas9 protein and/or alternatively a donor nucleic acid sequence, are used to deliver the CRISPR system to a target mitochondrial DNA sequence. According to this aspect, the CRISPR system is used to cut or nick the target mitochondrial DNA sequence or otherwise deliver a transcriptional regulator, such as a transcriptional activator or transcriptional repressor, to the target mitochondrial nucleic acid sequence.
According to one aspect, one or more mitochondria specific adeno-associated viruses (mito-AAV) which include a CRISPR system as described herein are used to deliver the CRISPR system to a target mitochondrial DNA sequence. According to this aspect, the CRISPR system is used to cut or nick the target mitochondrial DNA sequence or otherwise deliver a transcriptional regulator, such as a transcriptional activator or transcriptional repressor, to the target mitochondrial nucleic acid sequence.
According to certain aspects, a method of modulating expression of a target mitochondrial nucleic acid sequence in a mitochondria of a eukaryotic cell is provided including introducing into the mitochondria a first foreign nucleic acid encoding one or more guide RNAs complementary to one or more target mitochondrial nucleic acids, introducing into the mitochondria a second foreign nucleic acid encoding a Cas9 protein, such as a Cas9 enzyme, a Cas9 nickase or a nuclease null Cas9, introducing into the cell a third foreign
nucleic acid encoding a transcriptional regulator protein or domain, wherein the one or more guide RNAs, the Cas9 protein, and the transcriptional regulator protein or domain are expressed, wherein the one or more guide RNAs, the Cas9 protein and the transcriptional regulator protein or domain co-localize to the target mitochondrial nucleic acid sequence and wherein the transcriptional regulator protein or domain regulates expression of the target mitochondrial nucleic acid.
According to one aspect, the foreign nucleic acid encoding the Cas9 protein further encodes the transcriptional regulator protein or domain to create an expression product or fusion of the Cas9 attached to the transcriptional regulator protein or domain. According to one aspect, the foreign nucleic acid encoding one or more guide RNAs further encodes a target of an RNA-binding domain and the foreign nucleic acid encoding the transcriptional regulator protein or domain further encodes an RNA-binding domain fused to the transcriptional regulator protein or domain.
According to one aspect, the transcriptional regulator protein or domain is a transcriptional activator. According to one aspect, the transcriptional regulator protein or domain upregulates expression of the target mitochondrial nucleic acid. According to one aspect, the transcriptional regulator protein or domain upregulates expression of the target mitochondrial nucleic acid to treat a disease or detrimental condition. According to one aspect, the target mitochondrial nucleic acid is associated with a disease or detrimental condition. According to one aspect, the transcriptional regulator protein or domain is a transcriptional repressor. According to one aspect, the transcriptional regulator protein or domain downregulates expression of the target mitochondrial nucleic acid. According to one aspect, the transcriptional regulator protein or domain downregulates expression of the target mitochondrial nucleic acid to treat a disease or detrimental condition. According to one aspect, the target nucleic acid is associated with a disease or detrimental condition.
According to one aspect of altering a target mitochondrial nucleic acid, two or more guide RNAs may be used with a Cas9 nickase wherein the Cas9 nickase co-localizes with the two or more guide RNAs to the target mitochondrial nucleic acid and nicks the target mitochondrial nucleic acid resulting in two or more adjacent nicks. According to one aspect, the two or more adjacent nicks are on the same strand of the double stranded target mitochondrial nucleic acid. According to one aspect, the two or more adjacent nicks are on the same strand of the double stranded target mitochondrial nucleic acid and result in homologous recombination. According to one aspect, the two or more adjacent nicks are on different strands of the double stranded target mitochondrial nucleic acid. According to one aspect, the two or more adjacent nicks are on different strands of the double stranded target mitochondrial nucleic acid and create double stranded breaks. According to one aspect, the two or more adjacent nicks are on different strands of the double stranded target mitochondrial nucleic acid and create double stranded breaks resulting in nonhomologous end joining. According to one aspect, the two or more adjacent nicks are on different strands of the double stranded target mitochondrial nucleic acid and are offset with respect to one another. According to one aspect, the two or more adjacent nicks are on different strands of the double stranded target mitochondrial nucleic acid and are offset with respect to one another and create double stranded breaks. According to one aspect, the two or more adjacent nicks are on different strands of the double stranded target mitochondrial nucleic acid and are offset with respect to one another and create double stranded breaks resulting in nonhomologous end joining.
According to one aspect, the two or more adjacent nicks are on different strands of the double stranded DNA and create double stranded breaks resulting in fragmentation of the target nucleic acid thereby preventing expression of the target nucleic acid.
According to one aspect, the method further includes introducing into the cell a third foreign nucleic acid encoding a donor nucleic acid sequence wherein the two or more nicks results in incorporation of the donor nucleic acid sequence into the target mitochondrial nucleic acid through homologous recombination or nonhomologous end joining.
According to one aspect, a construct is provided that includes a mito-AAV and a nucleic acid encoding a Cas9 protein. According to another aspect, a construct is provided that includes a mito-AAV and a nucleic acid encoding a gRNA. According to one aspect, a construct is provided that includes a mito-AAV, a donor nucleic acid sequence and a nucleic acid sequence encoding a gRNA.
According to one aspect, a eukaryotic cell is provided wherein mitochondria therein include a nucleic acid encoding a guide RNA sequence complementary to a target mitochondrial nucleic acid sequence, a nucleic acid encoding a Cas9 enzyme that interacts with the guide RNA sequence and cleaves the target mitochondrial nucleic acid sequence in a site specific manner, wherein the mitochondria expresses the guide RNA and the Cas9 enzyme, the guide RNA binds to the complementary target nucleic acid and the Cas9 enzyme cleaves the target mitochondrial nucleic acid in a site specific manner.
According to another aspect, a eukaryotic cell is provided wherein mitochondria therein include a guide RNA sequence complementary to a target mitochondrial nucleic acid sequence, a donor nucleic acid sequence, and a Cas9 enzyme that interacts with the guide RNA sequence and cleaves the target mitochondrial nucleic acid sequence in a site specific manner, wherein the guide RNA sequence binds to the complementary target mitochondrial nucleic acid sequence and the Cas9 enzyme cleaves the target mitochondrial nucleic acid sequence in a site specific manner; and wherein the donor sequence is integrated into the mitochondrial nucleic acid sequence.
According to one aspect, a eukaryotic cell is provided wherein mitochondria therein include a guide RNA complementary to the target mitochondrial nucleic acid sequence, a Cas9 protein having inactive nuclease domains, wherein the Cas9 protein having inactive nuclease domains includes a transcriptional activator or repressor domain connected thereto for modulating target mitochondrial nucleic acid expression in vivo, wherein the guide RNA and the Cas9 protein including the transcriptional activator or repressor domain co-localize at the target mitochondrial nucleic acid sequence and wherein the transcriptional activator or repressor domain modulates expression of the target mitochondrial nucleic acid sequence.
According to one aspect, a eukaryotic cell is provided wherein mitochondria therein include a guide RNA complementary to the target mitochondrial nucleic acid sequence, with the guide RNA having a transcriptional activator or repressor domain connected thereto for modulating target mitochondrial nucleic acid expression in vivo, a Cas9 protein having inactive nuclease domains, wherein the guide RNA and the Cas9 protein co-localize at the target mitochondrial nucleic acid sequence and wherein the transcriptional activator or repressor domain modulates expression of the target mitochondrial nucleic acid sequence.
According to another aspect, a eukaryotic cell is provided wherein mitochondria therein include a guide RNA complementary to the target mitochondrial nucleic acid sequence, a Cas9 protein having inactive nuclease domains, a transcriptional activator or repressor domain for modulating target mitochondrial nucleic acid expression in vivo, wherein the transcriptional activator or repressor domain becomes attached to either the guide RNA or the Cas9 protein, wherein the guide RNA and the Cas9 protein co-localize at the target mitochondrial nucleic acid sequence and wherein the transcriptional activator or repressor domain modulates expression of the target mitochondrial nucleic acid sequence.
Further features and advantages of certain embodiments of the present invention will become more fully apparent in the following description of embodiments and drawings thereof, and from the claims.
BRIEF DESCRIPTION OF THE DRAWINGS
The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee. The foregoing and other features and advantages of the present invention will be more fully understood from the following detailed description of illustrative embodiments taken in conjunction with the accompanying drawings in which:
Fig. 1A to Fig. IB are directed to targeting mitochondria DNA using an engineered mi to- AAV. Fig. 1A is a schematic of rAAV-GFP. Fig. IB depicts in schematic the minimal CAG promoter (CAG), the minor or distal heavy-strand promoter (HSP) responsible for mRNA transcription in mitochondria; ATG start codon and ATA mitochondria specific start codon and AGA stop codon and AGG mitochondria specific stop codon. The AGA stop codon and AGG mitochondria specific stop codon were tested to confirm mitochondrial targeting. As shown in the images, mitochondria specific start codon or/and stop codon constrains the expression of rAAV-GFP specifically in the mitochondria, as evidenced in the colocalization of GFP and mito-tracker signal.
Fig. 2A to Fig. 2D are directed to genotype and phenotype data confirming mitochondrial genome engineering. Fig. 2 A is a schematic design of targeting the 16sRNA of mitochondria genome using mito-AAV-CRISPR system. Fig. 2B is a schematic showing co-transduction of mito-AAV-Cas9 with mito-AAV-donor-gRNA virus editing the mtDNA to confer CAP resistance in HT1080 and CAP resistance and MELAS variant in PGP1 iPS cells. Co-transduction of the two components generates a cut (dark triangle). The targeting
sequence (underline), PAM sequence of Cas9-ST, intended T2991C mutation (red) on RNR2 (16sRNA) and A3243G mutation (ref) on TRNL1 coding sequence are illustrated. The sequences of Donor DNA and gRNA are provided. Figure discloses SEQ ID NOS 10-11, respectively, in order of appearance. Fig. 2C depicts data demonstrating that HT1080 mitochondria are engineered with 0.6% homologous recombination (HR) efficiency and iPS cells are engineered with 0.3% HR efficiency. No difference between non-homologous end- joining (NHEJ) repair between positive and negative controls is measured. Fig. 2D depicts data demonstrating that engineered mitochondria are significantly more viable to concentrations of CAP after 7 days, ( t-test, *** p<0.001 ** p<0.05 N=3.)
Fig. 3A to Fig. 3B are directed to in vivo mitochondrial genome engineering. Fig. 3A is an image of mouse retina imaged using fluorescence microscopy. Green dots indicate transduced retinal cells expressing GFP. The mouse was sacrificed at 50 days after subretinal injections of AAV-CAG-GFP. Fig. 3B depicts data derived from GFP+ cells being enriched and sequenced to quantify HR efficiency as measured by deep sequencing. The average HR efficiency of each group is shown and error bars represent standard error from the mean.
Fig. 4 is a schematic of mito-AAV generation.
Fig. 5A depicts data directed to viral titer. Fig. 5B depicts data directed to infected cells.
Fig. 6A depicts data directed to homologous recombination efficiency of an engineered T2991C variant. Fig. 6B depicts data directed to homologous recombination efficiency of an evolved C2923A variant.
DETAILED DESCRIPTION
Embodiments of the present disclosure are directed to methods of targeting mitochondrial nucleic acid for editing or transcriptional regulation. According to one aspect,
one or more vectors are used to introduce one or more nucleic acids encoding a CRISPR system, i.e. a Cas9 protein and a guide RNA, and optionally a donor nucleic acid sequence, into mitochondria of a eukaryotic cell for editing or transcriptional regulation. The nucleic acids are expressed and the CRISPR system cuts or nicks the mitochondrial nucleic acid or otherwise delivers a transcriptional regulator to the mitochondrial nucleic acid. Together, a guide RNA and a Cas9 protein are referred to as a co-localization complex as that term is understood by one of skill in the art to the extent that the guide RNA and the Cas9 protein complex with a target mitochondrial nucleic acid. According to certain aspects, a vector may include one or more nucleic acids encoding a Cas9 protein, a guide RNA and/or a donor nucleic acid sequence. According to certain aspects, one or more nucleic acids encoding a Cas9 protein, a guide RNA and/or a donor nucleic acid sequence may be present within the same vector or present within different vectors.
According to one aspect, a vector is engineered to specifically target the mitochondria and deliver the one or more nucleic acids encoding a Cas9 protein, a guide RNA and/or a donor nucleic acid sequence into the mitochondria for expression by the mitochondrial DNA. According to one aspect, an exemplary vector includes a promoter responsible for mRNA transcription in mitochondria, a mitochondria specific start codon and a mitochondria specific stop codon. According to this aspect, expression of the one or more nucleic acids encoding a Cas9 protein, a guide RNA and/or a donor nucleic acid sequence is limited to expression within the mitochondria. According to one aspect, an exemplary vector is a mitochondria- specific adeno-associated virus, such as those known in the art. According to one aspect, a mitochondria-specific adeno-associated virus includes a nucleic acid encoding a Cas9 protein and promoters and codons to express the nucleic acid encoding a Cas9 protein within the mitochondria. According to one aspect, a mitochondria- specific adeno-associated virus
includes a nucleic acid encoding a guide RNA and promoters and codons to express the nucleic acid encoding the guide RNA within the mitochondria. According to one aspect, a mitochondria-specific adeno-associated virus includes a donor nucleic acid sequence or a nucleic acid encoding a donor nucleic acid sequence to provide the donor nucleic acid sequence within the mitochondria or otherwise Cas9 protein and promoters and codons to express the nucleic acid encoding the donor nucleic acid sequence under operation of a suitable promoter and start and stop codons within the mitochondria. According to one aspect, a mitochondria- specific adeno-associated virus includes a nucleic acid encoding a Cas9 protein, a nucleic acid encoding a guide RNA and a nucleic acid encoding the donor nucleic sequence and a suitable promoter(s) and start and stop codon(s). According to one aspect, a mitochondria- specific adeno-associated virus includes a nucleic acid encoding a guide RNA and a nucleic acid encoding the donor nucleic sequence and a suitable promoter(s) and start and stop codon(s).
CAS9 DESCRIPTION
RNA guided DNA binding proteins are readily known to those of skill in the art to bind to DNA for various purposes. Such DNA binding proteins may be naturally occurring. DNA binding proteins having nuclease activity are known to those of skill in the art, and include naturally occurring DNA binding proteins having nuclease activity, such as Cas9 proteins present, for example, in Type II CRISPR systems. Such Cas9 proteins and Type II CRISPR systems are well documented in the art. See Makarova et al., Nature Reviews, Microbiology, Vol. 9, June 2011, pp. 467-477 including all supplementary information hereby incorporated by reference in its entirety.
In general, bacterial and archaeal CRISPR-Cas systems rely on short guide RNAs in complex with Cas proteins to direct degradation of complementary sequences present within
invading foreign nucleic acid. See Deltcheva, E. et al. CRISPR RNA maturation by trans- encoded small RNA and host factor RNase III. Nature 471, 602-607 (2011); Gasiunas, G., Barrangou, R., Horvath, P. & Siksnys, V. Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proceedings of the National Academy of Sciences of the United States of America 109, E2579-2586 (2012); Jinek, M. et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816-821 (2012); Sapranauskas, R. et al. The Streptococcus thermophilus CRISPR/Cas system provides immunity in Escherichia coli. Nucleic acids research 39, 9275- 9282 (2011); and Bhaya, D., Davison, M. & Barrangou, R. CRISPR-Cas systems in bacteria and archaea: versatile small RNAs for adaptive defense and regulation. Annual review of genetics 45, 273-297 (2011). A recent in vitro reconstitution of the S. pyogenes type II CRISPR system demonstrated that crRNA ("CRISPR RNA") fused to a normally trans- encoded tracrRNA ("trans-activating CRISPR RNA") is sufficient to direct Cas9 protein to sequence-specifically cleave target DNA sequences matching the crRNA. Expressing a gRNA homologous to a target site results in Cas9 recruitment and degradation of the target DNA. See H. Deveau et al. , Phage response to CRISPR-encoded resistance in Streptococcus thermophilus. Journal of Bacteriology 190, 1390 (Feb, 2008).
Three classes of CRISPR systems are generally known and are referred to as Type I, Type II or Type III). According to one aspect, a particular useful enzyme according to the present disclosure to cleave dsDNA is the single effector enzyme, Cas9, common to Type II. See K. S. Makarova et al , Evolution and classification of the CRISPR-Cas systems. Nature reviews. Microbiology 9, 467 (Jun, 2011) hereby incorporated by reference in its entirety. Within bacteria, the Type II effector system consists of a long pre-crRNA transcribed from the spacer-containing CRISPR locus, the multifunctional Cas9 protein, and a tracrRNA important for gRNA processing. The tracrRNAs hybridize to the repeat regions separating
the spacers of the pre-crRNA, initiating dsRNA cleavage by endogenous RNase III, which is followed by a second cleavage event within each spacer by Cas9, producing mature crRNAs that remain associated with the tracrRNA and Cas9. TracrRNA-crRNA fusions are contemplated for use in the present methods.
According to one aspect, the enzyme of the present disclosure, such as Cas9 unwinds the DNA duplex and searches for sequences matching the crRNA to cleave. Target recognition occurs upon detection of complementarity between a "protospacer" sequence in the target DNA and the remaining spacer sequence in the crRNA. Importantly, Cas9 cuts the DNA only if a correct protospacer-adjacent motif (PAM) is also present at the 3' end. According to certain aspects, different protospacer-adjacent motif can be utilized. For example, the S. pyogenes system requires an NGG sequence, where N can be any nucleotide. S. thermophilus Type II systems require NGGNG (see P. Horvath, R. Barrangou, CRISPR/Cas, the immune system of bacteria and archaea. Science 327, 167 (Jan 8, 2010) hereby incorporated by reference in its entirety and NNAGAAW (see H. Deveau et al. , Phage response to CRISPR-encoded resistance in Streptococcus thermophilus. Journal of bacteriology 190, 1390 (Feb, 2008) hereby incorporatd by reference in its entirety), respectively, while different S. mutans systems tolerate NGG or NAAR (see J. R. van der Ploeg, Analysis of CRISPR in Streptococcus mutans suggests frequent occurrence of acquired immunity against infection by M102-like bacteriophages. Microbiology 155, 1966 (Jun, 2009) hereby incorporated by refernece in its entirety. Bioinformatic analyses have generated extensive databases of CRISPR loci in a variety of bacteria that may serve to identify additional useful PAMs and expand the set of CRISPR-targetable sequences (see M. Rho, Y. W. Wu, H. Tang, T. G. Doak, Y. Ye, Diverse CRISPRs evolving in human microbiomes. PLoS genetics 8, el002441 (2012) and D. T. Pride et al. , Analysis of streptococcal CRISPRs from human saliva reveals substantial sequence diversity within and
between subjects over time. Genome research 21, 126 (Jan, 2011) each of which are hereby incorporated by reference in their entireties.
In S. pyogenes, Cas9 generates a blunt-ended double- stranded break 3bp upstream of the pro tospacer- adjacent motif (PAM) via a process mediated by two catalytic domains in the protein: an HNH domain that cleaves the complementary strand of the DNA and a RuvC-like domain that cleaves the non-complementary strand. See Jinek et al., Science 337, 816-821 (2012) hereby incorporated by reference in its entirety. Cas9 proteins are known to exist in many Type II CRISPR systems including the following as identified in the supplementary information to Makarova et al., Nature Reviews, Microbiology, Vol. 9, June 2011, pp. 467- 477: Methanococcus maripaludis C7; Corynebacterium diphtheriae; Corynebacterium efficiens YS-314; Corynebacterium glutamicum ATCC 13032 Kitasato; Corynebacterium glutamicum ATCC 13032 Bielefeld; Corynebacterium glutamicum R; Corynebacterium kroppenstedtii DSM 44385; Mycobacterium abscessus ATCC 19977; Nocardia farcinica IFM10152; Rhodococcus erythropolis PR4; Rhodococcus jostii RHA1; Rhodococcus opacus B4 uid36573; Acidothermus cellulolyticus 11B; Arthrobacter chlorophenolicus A6; Kribbella flavida DSM 17836 uid43465; Thermomonospora curvata DSM 43183; Bifidobacterium dentium Bdl ; Bifidobacterium longum DJO10A; Slackia heliotrinireducens DSM 20476; Persephonella marina EX HI ; Bacteroides fragilis NCTC 9434; Capnocytophaga ochracea DSM 7271; Flavobacterium psychrophilum JIP02 86; Akkermansia muciniphila ATCC BAA 835; Roseiflexus castenholzii DSM 13941 ; Roseiflexus RSI ; Synechocystis PCC6803; Elusimicrobium minutum Peil91; uncultured Termite group 1 bacterium phylotype Rs D17; Fibrobacter succinogenes S85; Bacillus cereus ATCC 10987; Listeria innocua;Lactobacillus casei; Lactobacillus rhamnosus GG; Lactobacillus salivarius UCC118; Streptococcus agalactiae A909; Streptococcus agalactiae NEM316; Streptococcus agalactiae 2603; Streptococcus dysgalactiae equisimilis GGS 124; Streptococcus equi zooepidemicus
MGCS10565; Streptococcus gallolyticus UCN34 uid46061; Streptococcus gordonii Challis subst CHI; Streptococcus mutans NN2025 uid46353; Streptococcus mutans; Streptococcus pyogenes Ml GAS; Streptococcus pyogenes MGAS5005; Streptococcus pyogenes MGAS2096; Streptococcus pyogenes MGAS9429; Streptococcus pyogenes MGAS 10270; Streptococcus pyogenes MGAS6180; Streptococcus pyogenes MGAS315; Streptococcus pyogenes SSI-1; Streptococcus pyogenes MGAS 10750; Streptococcus pyogenes NZ131; Streptococcus thermophiles CNRZ1066; Streptococcus thermophiles LMD-9; Streptococcus thermophiles LMG 18311; Clostridium botulinum A3 Loch Maree; Clostridium botulinum B Eklund 17B; Clostridium botulinum Ba4 657; Clostridium botulinum F Langeland; Clostridium cellulolyticum H10; Finegoldia magna ATCC 29328; Eubacterium rectale ATCC 33656; Mycoplasma gallisepticum; Mycoplasma mobile 163K; Mycoplasma penetrans; Mycoplasma synoviae 53; Streptobacillus moniliformis DSM 12112; Bradyrhizobium BTAil; Nitrobacter hamburgensis X14; Rhodopseudomonas palustris BisB18; Rhodopseudomonas palustris BisB5; Parvibaculum lavamentivorans DS-1; Dinoroseobacter shibae DFL 12; Gluconacetobacter diazotrophicus Pal 5 FAPERJ; Gluconacetobacter diazotrophicus Pal 5 JGI; Azospirillum B510 uid46085; Rhodospirillum rubrum ATCC 11170; Diaphorobacter TPSY uid29975; Verminephrobacter eiseniae EF01-2; Neisseria meningitides 053442; Neisseria meningitides alphal4; Neisseria meningitides Z2491; Desulfo vibrio salexigens DSM 2638; Campylobacter jejuni doylei 269 97; Campylobacter jejuni 81116; Campylobacter jejuni; Campylobacter lari RM2100; Helicobacter hepaticus; Wolinella succinogenes; Tolumonas auensis DSM 9187; Pseudoalteromonas atlantica T6c; Shewanella pealeana ATCC 700345; Legionella pneumophila Paris; Actinobacillus succinogenes 130Z; Pasteurella multocida; Francisella tularensis novicida U112; Francisella tularensis holarctica; Francisella tularensis FSC 198; Francisella tularensis tularensis; Francisella tularensis WY96-3418; and Treponema denticola
ATCC 35405. The Cas9 protein may be referred by one of skill in the art in the literature as Csnl. An exemplary S. pyogenes Cas9 protein sequence is provided in Deltcheva et al., Nature All, 602-607 (2011) hereby incorporated by reference in its entirety.
Modification to the Cas9 protein is a representative embodiment of the present disclosure. CRISPR systems useful in the present disclosure are described in R. Barrangou, P. Horvath, CRISPR: new horizons in phage resistance and strain identification. Annual review of food science and technology 3, 143 (2012) and B. Wiedenheft, S. H. Sternberg, J. A. Doudna, RNA-guided genetic silencing systems in bacteria and archaea. Nature 482, 331 (Feb 16, 2012) each of which are hereby incorporated by reference in their entireties.
According to certain aspects, the DNA binding protein is altered or otherwise modified to inactivate the nuclease activity. Such alteration or modification includes altering one or more amino acids to inactivate the nuclease activity or the nuclease domain. Such modification includes removing the polypeptide sequence or polypeptide sequences exhibiting nuclease activity, i.e. the nuclease domain, such that the polypeptide sequence or polypeptide sequences exhibiting nuclease activity, i.e. nuclease domain, are absent from the DNA binding protein. Other modifications to inactivate nuclease activity will be readily apparent to one of skill in the art based on the present disclosure. Accordingly, a nuclease- null DNA binding protein includes polypeptide sequences modified to inactivate nuclease activity or removal of a polypeptide sequence or sequences to inactivate nuclease activity. The nuclease-null DNA binding protein retains the ability to bind to DNA even though the nuclease activity has been inactivated. Accordingly, the DNA binding protein includes the polypeptide sequence or sequences required for DNA binding but may lack the one or more or all of the nuclease sequences exhibiting nuclease activity. Accordingly, the DNA binding protein includes the polypeptide sequence or sequences required for DNA binding but may have one or more or all of the nuclease sequences exhibiting nuclease activity inactivated.
According to one aspect, a DNA binding protein having two or more nuclease domains may be modified or altered to inactivate all but one of the nuclease domains. Such a modified or altered DNA binding protein is referred to as a DNA binding protein nickase, to the extent that the DNA binding protein cuts or nicks only one strand of double stranded DNA. When guided by RNA to DNA, the DNA binding protein nickase is referred to as an RNA guided DNA binding protein nickase. An exemplary DNA binding protein is an RNA guided DNA binding protein nuclease of a Type II CRISPR System, such as a Cas9 protein or modified Cas9 or homolog of Cas9. An exemplary DNA binding protein is a Cas9 protein nickase. An exemplary DNA binding protein is an RNA guided DNA binding protein of a Type II CRISPR System which lacks nuclease activity. An exemplary DNA binding protein is a nuclease-null or nuclease deficient Cas9 protein.
According to an additional aspect, nuclease-null Cas9 proteins are provided where one or more amino acids in Cas9 are altered or otherwise removed to provide nuclease-null Cas9 proteins. According to one aspect, the amino acids include D10 and H840. See Jinek et al., Science 337, 816-821 (2012). According to an additional aspect, the amino acids include D839 and N863. According to one aspect, one or more or all of D10, H840, D839 and H863 are substituted with an amino acid which reduces, substantially eliminates or eliminates nuclease activity. According to one aspect, one or more or all of D10, H840, D839 and H863 are substituted with alanine. According to one aspect, a Cas9 protein having one or more or all of D10, H840, D839 and H863 substituted with an amino acid which reduces, substantially eliminates or eliminates nuclease activity, such as alanine, is referred to as a nuclease-null Cas9 ("Cas9Nuc") and exhibits reduced or eliminated nuclease activity, or nuclease activity is absent or substantially absent within levels of detection. According to this aspect, nuclease activity for a Cas9Nuc may be undetectable using known assays, i.e. below the level of detection of known assays.
According to one aspect, the Cas9 protein, Cas9 protein nickase or nuclease null Cas9 includes homologs and orthologs thereof which retain the ability of the protein to bind to the DNA and be guided by the RNA. According to one aspect, the Cas9 protein includes the sequence as set forth for naturally occurring Cas9 from S. thermophiles or S. pyogenes and protein sequences having at least 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98% or 99% homology thereto and being a DNA binding protein, such as an RNA guided DNA binding protein.
An exemplary CRISPR system includes the S. thermophiles Cas9 nuclease (ST1 Cas9) (see Esvelt KM, et al., Orthogonal Cas9 proteins for RNA-guided gene regulation and editing, Nature Methods., (2013) hereby incorporated by reference in its entirety).An exemplary CRISPR system includes the S. pyogenes Cas9 nuclease (Sp. Cas9), an extremely high-affinity (see Sternberg, S.H., Redding, S., Jinek, M., Greene, E.C. & Doudna, J.A. DNA interrogation by the CRISPR RNA-guided endonuclease Cas9. Nature 507, 62-67 (2014) hereby incorporated by reference in its entirety), programmable DNA-binding protein isolated from a type II CRISPR-associated system (see Garneau, J.E. et al. The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA. Nature 468, 67-71 (2010) and Jinek, M. et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816-821 (2012) each of which are hereby incorporated by reference in its entirety). According to certain aspects, a nuclease null or nuclease deficient Cas 9 can be used in the methods described herein. Such nuclease null or nuclease deficient Cas9 proteins are described in Gilbert, L.A. et al. CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell 154, 442-451 (2013); Mali, P. et al. CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nature biotechnology 31, 833-838 (2013); Maeder, M.L. et al. CRISPR RNA-guided activation of endogenous human genes. Nature methods 10, 977-979 (2013);
and Perez-Pinera, P. et al. RNA-guided gene activation by CRISPR-Cas9-based transcription factors. Nature methods 10, 973-976 (2013) each of which are hereby incorporated by reference in its entirety. The DNA locus targeted by Cas9 (and by its nuclease-deficient mutant, "dCas9" precedes a three nucleotide (nt) 5 NGG-3 ' "PAM" sequence, and matches a 15-22-nt guide or spacer sequence within a Cas9-bound RNA cof actor, referred to herein and in the art as a guide RNA. Altering this guide RNA is sufficient to target Cas9 or a nuclease deficient Cas9 to a target nucleic acid. In a multitude of CRISPR-based biotechnology applications (see Mali, P., Esvelt, K.M. & Church, G.M. Cas9 as a versatile tool for engineering biology. Nature methods 10, 957-963 (2013); Hsu, P.D., Lander, E.S. & Zhang, F. Development and Applications of CRISPR-Cas9 for Genome Engineering. Cell 157, 1262- 1278 (2014); Chen, B. et al. Dynamic imaging of genomic loci in living human cells by an optimized CRISPR/Cas system. Cell 155, 1479-1491 (2013); Shalem, O. et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343, 84-87 (2014); Wang, T., Wei, J.J., Sabatini, D.M. & Lander, E.S. Genetic screens in human cells using the CRISPR- Cas9 system. Science 343, 80-84 (2014); Nissim, L., Perli, S.D., Fridkin, A., Perez-Pinera, P. & Lu, T.K. Multiplexed and Programmable Regulation of Gene Networks with an Integrated RNA and CRISPR/Cas Toolkit in Human Cells. Molecular cell 54, 698-710 (2014); Ryan, O.W. et al. Selection of chromosomal DNA libraries using a multiplex CRISPR system. eLife 3 (2014); Gilbert, L.A. et al. Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation. Cell (2014); and Citorik, R.J., Mimee, M. & Lu, T.K. Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases. Nature biotechnology (2014) each of which are hereby incorporated by reference in its entirety), the guide is often presented in a so-called sgRNA (single guide RNA), wherein the two natural Cas9 RNA cofactors (gRNA and tracrRNA) are fused via an ngineered loop or linker.
According to one aspect, the Cas9 protein is an enzymatically active Cas9 protein, a Cas9 protein wild-type protein, a Cas9 protein nickase or a nuclease null or nuclease deficient Cas9 protein. Additional exemplary Cas9 proteins include Cas9 proteins attached to, bound to or fused with functional proteins such as transcriptional regulators, such as transcriptional activators or repressors, a Fok-domain, such as Fok 1, an aptamer, a binding protein, PP7, MS2 and the like.
According to certain aspects, the Cas9 protein may be delivered directly to a cell by methods known to those of skill in the art, including injection or lipofection, or as translated from its cognate mRNA, or transcribed from its cognate DNA into mRNA (and thereafter translated into protein). Cas9 DNA and mRNA may be themselves introduced into cells through electroporation, transient and stable transfection (including lipofection) and viral transduction or other methods known to those of skill in the art.
GUIDE RNA DESCRIPTION
Embodiments of the present disclosure are directed to the use of a CRISPR/Cas system and, in particular, a guide RNA which may include one or more of a spacer sequence, a tracr mate sequence and a tracr sequence. The term spacer sequence is understood by those of skill in the art and may include any polynucleotide having sufficient complementarity with a target nucleic acid sequence to hybridize with the target nucleic acid sequence and direct sequence-specific binding of a CRISPR complex to the target sequence. The guide RNA may be formed from a spacer sequence covalently connected to a tracr mate sequence (which may be referred to as a crRNA) and a separate tracr sequence, wherein the tracr mate sequence is hybridized to a portion of the tracr sequence. According to certain aspects, the tracr mate sequence and the tracr sequence are connected or linked such as by covalent bonds by a linker sequence, which construct may be referred to as a fusion of the tracr mate
sequence and the tracr sequence. The linker sequence referred to herein is a sequence of nucleotides, referred to herein as a nucleic acid sequence, which connect the tracr mate sequence and the tracr sequence. Accordingly, a guide RNA may be a two component species (i.e., separate crRNA and tracr RNA which hybridize together) or a unimolecular species (i.e., a crRNA-tracr RNA fusion, often termed an sgRNA).
According to certain aspects, the guide RNA is between about 10 to about 500 nucleotides. According to one aspect, the guide RNA is between about 20 to about 100 nucleotides. According to certain aspects, the spacer sequence is between about 10 and about 500 nucleotides in length. According to certain aspects, the tracr mate sequence is between about 10 and about 500 nucleotides in length. According to certain aspects, the tracr sequence is between about 10 and about 100 nucleotides in length. According to certain aspects, the linker nucleic acid sequence is between about 10 and about 100 nucleotides in length.
According to one aspect, embodiments described herein include guide RNA having a length including the sum of the lengths of a spacer sequence, tracr mate sequence, tracr sequence, and linker sequence (if present). Accordingly, such a guide RNA may be described by its total length which is a sum of its spacer sequence, tracr mate sequence, tracr sequence, and linker sequence (if present). According to this aspect, all of the ranges for the spacer sequence, tracr mate sequence, tracr sequence, and linker sequence (if present) are incorporated herein by reference and need not be repeated. A guide RNA as described herein may have a total length based on summing values provided by the ranges described herein. Aspects of the present disclosure are directed to methods of making such guide RNAs as described herein by expressing constructs encoding such guide RNA using promoters and terminators and optionally other genetic elements as described herein.
According to certain aspects, the guide RNA may be delivered directly to a cell as a
native species by methods known to those of skill in the art, including injection or lipofection, or as transcribed from its cognate DNA, with the cognate DNA introduced into cells through electroporation, transient and stable transfection (including lipofection) and viral transduction.
DONOR DESCRIPTION
The term "donor nucleic acid" include a nucleic acid sequence which is to be inserted into mitochondrial DNA according to methods described herein for expression by the mitochondrial DNA. The donor nucleic acid sequence may be expressed by the cell.
According to one aspect, the donor nucleic acid is exogenous to the cell. According to one aspect, the donor nucleic acid is foreign to the cell. According to one aspect, the donor nucleic acid is non-naturally occurring within the cell.
TRANSCRIPTION REGULATOR DESCRIPTION
According to one aspect, an engineered Cas9-gRNA system is provided which enables RNA-guided mitochondrial DNA regulation in human cells by tethering transcriptional activation domains to either a nuclease-null Cas9 or to guide RNAs. According to one aspect of the present disclosure, one or more transcriptional regulatory proteins or domains (such terms are used interchangeably) are joined or otherwise connected to a nuclease-deficient Cas9 or one or more guide RNA (gRNA). The transcriptional regulatory domains correspond to targeted loci. Accordingly, aspects of the present disclosure include methods and materials for localizing transcriptional regulatory domains to targeted loci by fusing, connecting or joining such domains to either Cas9N or to the gRNA.
According to one aspect, a Cas9N-fusion protein capable of transcriptional activation is provided. According to one aspect, a VP64 activation domain (see Zhang et al., Nature
Biotechnology 29, 149-153 (2011) hereby incorporated by reference in its entirety) is joined, fused, connected or otherwise tethered to the C terminus of Cas9N. According to one method, the transcriptional regulatory domain is provided to the site of target mitochondrial DNA by the Cas9N protein. According to one method, a Cas9N fused to a transcriptional regulatory domain is provided within a cell along with one or more guide RNAs. The Cas9N with the transcriptional regulatory domain fused thereto bind at or near target mitochondrial DNA. The one or more guide RNAs bind at or near target mitochondrial DNA. The transcriptional regulatory domain regulates expression of the target mitochondrial nucleic acid sequence. According to a specific aspect, a Cas9N-VP64 fusion activated transcription of reporter constructs when combined with gRNAs targeting sequences near the promoter, thereby displaying RNA-guided transcriptional activation.
According to one aspect, a gRNA-fusion protein capable of transcriptional activation is provided. According to one aspect, a VP64 activation domain is joined, fused, connected or otherwise tethered to the gRNA. According to one method, the transcriptional regulatory domain is provided to the site of target mitochondrial DNA by the gRNA. According to one method, a gRNA fused to a transcriptional regulatory domain is provided within a cell along with a Cas9N protein. The Cas9N binds at or near target mitochondrial DNA. The one or more guide RNAs with the transcriptional regulatory protein or domain fused thereto bind at or near target mitochondrial DNA. The transcriptional regulatory domain regulates expression of the target gene. According to a specific aspect, a Cas9N protein and a gRNA fused with a transcriptional regulatory domain activated transcription of reporter constructs, thereby displaying RNA-guided transcriptional activation.
Transcriptional regulator proteins or domains which are transcriptional activators include VP16 and VP64 and others readily identifiable by those skilled in the art based on the present disclosure.
TARGET MITOCHONDRIAL NUCLEIC ACID
Target mitochondrial nucleic acids include any nucleic acid sequence within mitochondrial DNA to which a co-localization complex as described herein can be useful to either cut, nick or regulate. Target nucleic acids include mitochondrial nucleic acid sequences capable of being expressed into proteins. For purposes of the present disclosure, mitochondrial DNA, such as double stranded mitochondrial DNA, can include the target mitochondrial nucleic acid and a co-localization complex can bind to or otherwise co-localize with the mitochondrial DNA at or adjacent or near the target mitochondrial nucleic acid and in a manner in which the co-localization complex may have a desired effect on the target mitochondrial nucleic acid. One of skill based on the present disclosure will readily be able to identify or design guide RNAs and Cas9 proteins which co-localize to a mitochondrial DNA including a target mitochondrial nucleic acid. One of skill will further be able to identify transcriptional regulator proteins or domains which likewise co-localize to a mitochondrial DNA including a target mitochondrial nucleic acid.
FOREIGN NUCLEIC ACIDS DESCRIPTION
Foreign nucleic acids (i.e. those which are not part of a cell's natural nucleic acid composition) may be introduced into a cell using any method known to those skilled in the art for such introduction. Such methods include transfection, transduction, viral transduction, microinjection, lipofection, nucleofection, nanoparticle bombardment, transformation, conjugation and the like. One of skill in the art will readily understand and adapt such methods using readily identifiable literature sources.
CELLS
Cells according to the present disclosure include any cell into which foreign nucleic acids can be introduced and expressed as described herein. It is to be understood that the
basic concepts of the present disclosure described herein are not limited by cell type. Cells according to the present disclosure include eukaryotic cells, prokaryotic cells, animal cells, plant cells, fungal cells, archael cells, eubacterial cells and the like. Cells include eukaryotic cells such as yeast cells, plant cells, and animal cells. Particular cells include mammalian cells. Further, cells include any in which it would be beneficial or desirable to cut, nick or regulate a target nucleic acid. Such cells may include those which are deficient in expression of a particular protein within the mitochondria leading to a disease or detrimental condition. Such diseases or detrimental conditions are readily known to those of skill in the art. According to the present disclosure, the nucleic acid responsible for expressing the particular protein may be targeted by the methods described herein and a transcriptional activator resulting in upregulation of the target nucleic acid and corresponding expression of the particular protein. In this manner, the methods described herein provide therapeutic treatment. Such cells may include those which are over express a particular protein in the mitochondria leading to a disease or detrimental condition. Such diseases or detrimental conditions are readily known to those of skill in the art. According to the present disclosure, the nucleic acid responsible for expressing the particular protein may be targeted by the methods described herein and a transcriptional depressor resulting in downregulation of the target nucleic acid and corresponding expression of the particular protein. In this manner, the methods described herein provide therapeutic treatment.
According to one aspect, the cell is a eukaryotic cell. According to one aspect, the cell is a yeast cell, a plant cell or an animal cell. According to one aspect, the cell is a mammalian cell. According to one aspect, the cell is a human cell. According to one aspect, the cell is a stem cell whether adult or embryonic. According to one aspect, the cell is a pluripotent stem cell. According to one aspect, the cell is an induced pluripotent stem cell. According to one aspect, the cell is a human induced pluripotent stem cell.
VECTORS
Vectors are contemplated for use with the methods and constructs described herein. The term "vector" includes a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. Vectors used to deliver the nucleic acids to cells as described herein include vectors known to those of skill in the art and used for such purposes. Certain exemplary vectors may be plasmids, lentiviruses or adeno-associated viruses known to those of skill in the art. Vectors include, but are not limited to, nucleic acid molecules that are single- stranded, doublestranded, or partially double-stranded; nucleic acid molecules that comprise one or more free ends, no free ends (e.g. circular); nucleic acid molecules that comprise DNA, RNA, or both; and other varieties of polynucleotides known in the art. One type of vector is a "plasmid," which refers to a circular double stranded DNA loop into which additional DNA segments can be inserted, such as by standard molecular cloning techniques. Another type of vector is a viral vector, wherein virally-derived DNA or RNA sequences are present in the vector for packaging into a virus (e.g. retroviruses, lentiviruses, replication defective retroviruses, adenoviruses, replication defective adenoviruses, and adeno-associated viruses). Viral vectors also include polynucleotides carried by a virus for transfection into a host cell. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g. bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as "expression vectors." Common expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. Recombinant expression vectors can comprise
a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory elements, which may be selected on the basis of the host cells to be used for expression, that is operatively-linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, "operably linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory element(s) in a manner that allows for expression of the nucleotide sequence (e.g. in an in vitro transcription/translation system or in a host cell when the vector is introduced into the host cell).
Methods of non-viral delivery of nucleic acids or native DNA binding protein, native guide RNA or other native species include lipofection, microinjection, biolistics, virosomes, liposomes, immunoliposomes, polycation or lipid:nucleic acid conjugates, naked DNA, artificial virions, and agent-enhanced uptake of DNA. Lipofection is described in e.g., U.S. Pat. Nos. 5,049,386, 4,946,787; and 4,897,355) and lipofection reagents are sold commercially (e.g., Transfectam™ and Lipofectin™). Cationic and neutral lipids that are suitable for efficient receptor-recognition lipofection of polynucleotides include those of Feigner, WO 91/17424; WO 91/16024. Delivery can be to cells (e.g. in vitro or ex vivo administration) or target tissues (e.g. in vivo administration). The term native includes the protein, enzyme or guide RNA species itself and not the nucleic acid encoding the species. According to certain aspects, the vectors are engineered to specifically target to mitochondria and/or codon optimized for mitochondrial specific delivery of the nucleic acid sequences within the vectors.
REGULATORY ELEMENTS AND TERMINATORS AND TAGS
Regulatory elements are contemplated for use with the methods and constructs described herein. The term "regulatory element" is intended to include promoters, enhancers,
internal ribosomal entry sites (IRES), and other expression control elements (e.g. transcription termination signals, such as polyadenylation signals and poly-U sequences). Such regulatory elements are described, for example, in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Regulatory elements include those that direct constitutive expression of a nucleotide sequence in many types of host cell and those that direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). A tissue- specific promoter may direct expression primarily in a desired tissue of interest, such as muscle, neuron, bone, skin, blood, specific organs (e.g. liver, pancreas), or particular cell types (e.g. lymphocytes). Regulatory elements may also direct expression in a temporal- dependent manner, such as in a cell-cycle dependent or developmental stage-dependent manner, which may or may not also be tissue or cell-type specific. In some embodiments, a vector may comprise one or more pol III promoter (e.g. 1, 2, 3, 4, 5, or more pol III promoters), one or more pol II promoters (e.g. 1, 2, 3, 4, 5, or more pol II promoters), one or more pol I promoters (e.g. 1, 2, 3, 4, 5, or more pol I promoters), or combinations thereof. Examples of pol III promoters include, but are not limited to, U6 and HI promoters. Examples of pol II promoters include, but are not limited to, the retroviral Rous sarcoma virus (RSV) LTR promoter (optionally with the RSV enhancer), the cytomegalovirus (CMV) promoter (optionally with the CMV enhancer) [see, e.g., Boshart et al, Cell, 41:521-530 (1985)], the SV40 promoter, the dihydrofolate reductase promoter, the β-actin promoter, the phosphoglycerol kinase (PGK) promoter, and the EFla promoter and Pol II promoters described herein. Also encompassed by the term "regulatory element" are enhancer elements, such as WPRE; CMV enhancers; the R-U5' segment in LTR of HTLV-I (Mol. Cell. Biol., Vol. 8(1), p. 466-472, 1988); SV40 enhancer; and the intron sequence between exons 2 and 3 of rabbit β-globin (Proc. Natl. Acad. Sci. USA., Vol. 78(3), p. 1527-31, 1981). It will be
appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression desired, etc. A vector can be introduced into host cells to thereby produce transcripts, proteins, or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (e.g., clustered regularly interspersed short palindromic repeats (CRISPR) transcripts, proteins, enzymes, mutant forms thereof, fusion proteins thereof, etc.).
Aspects of the methods described herein may make use of terminator sequences. A terminator sequence includes a section of nucleic acid sequence that marks the end of a gene or operon in genomic DNA during transcription. This sequence mediates transcriptional termination by providing signals in the newly synthesized mRNA that trigger processes which release the mRNA from the transcriptional complex. These processes include the direct interaction of the mRNA secondary structure with the complex and/or the indirect activities of recruited termination factors. Release of the transcriptional complex frees RNA polymerase and related transcriptional machinery to begin transcription of new mRNAs. Terminator sequences include those known in the art and identified and described herein.
Aspects of the methods described herein may make use of epitope tags and reporter gene sequences. Non-limiting examples of epitope tags include histidine (His) tags, V5 tags, FLAG tags, influenza hemagglutinin (HA) tags, Myc tags, VSV-G tags, and thioredoxin (Trx) tags. Examples of reporter genes include, but are not limited to, glutathione-S- transferase (GST), horseradish peroxidase (HRP), chloramphenicol acetyltransferase (CAT) beta-galactosidase, betaglucuronidase, luciferase, green fluorescent protein (GFP), HcRed, DsRed, cyan fluorescent protein (CFP), yellow fluorescent protein (YFP), and autofluorescent proteins including blue fluorescent protein (BFP).
DELIVERY DESCRIPTION
Embodiments of the present disclosure are directed to a method of delivering a Cas9 protein to cells within a subject comprising administering to the subject, such as systemically administering to the subject, such as by intravenous administration or injection, intraperitoneal administration or injection, intramuscular administration or injection, intracranial administration or injection, intraocular administration or injection, subcutaneous administration or injection, a Cas9 protein or a nucleic acid encoding the Cas9 protein.
Embodiments of the present disclosure are directed to a method of delivering a guide RNA having an RNA domain (selected RNA sequence) attached thereto to cells within a subject comprising administering to the subject, such as systemically administering to the subject, such as by intravenous administration or injection, intraperitoneal administration or injection, intramuscular administration or injection, intracranial administration or injection, intraocular administration or injection, subcutaneous administration or injection, a guide RNA or a nucleic acid encoding the guide RNA.
Embodiments of the present disclosure are directed to a method of delivering a Cas9 protein and a guide RNA to cells within a subject comprising administering to the subject, such as systemically administering to the subject, such as by intravenous administration or injection, intraperitoneal administration or injection, intramuscular administration or injection, intracranial administration or injection, intraocular administration or injection, subcutaneous administration or injection, a Cas9 protein or a nucleic acid encoding the Cas9 protein and a guide RNA or a nucleic acid encoding the guide RNA.
DISEASES AND CONDITIONS ASSOCIATED WITH MITOCHONDRIAL DNA
Mitochondrial mutations trigger various degenerative disorder, cancer, and aging. Mitochondria dysfunction causes various fatal age-related and degenerative disorders. See D. C. Wallace, Mitochondrial diseases in man and mouse. Science 283, 1482-1488 (1999); F.
Terasaki, M. Tanaka, K. Kawamura, Y. Kanzaki, M. Okabe, T. Hayashi, H. Shimomura, T. Ito, M. Suwa, J. S. Gong, J. Zhang, Y. Kitaura, A case of cardiomyopathy showing progression from the hypertrophic to the dilated form: association of Mt8348A— >G mutation in the mitochondrial tRNA(Lys) gene with severe ultrastructural alterations of mitochondria in cardiomyocytes. Jpn Circ J 65, 691-694 (2001); G. M. Martin, L. A. Loeb, Ageing: mice and mitochondria. Nature 429, 357-359 (2004); S. G. Jarrett, A. S. Lewin, M. E. Boulton, The importance of mitochondria in age-related and inherited eye disorders. Ophthalmic research 44, 179-190 (2010); O. Z. Karicheva, O. A. Kolesnikova, T. Schirtz, M. Y. Vysokikh, A. M. Mager-Heckel, A. Lombes, A. Boucheham, I. A. Krasheninnikov, R. P. Martin, N. Entelis, I. Tarassov, Correction of the consequences of mitochondrial 3243A>G mutation in the MT-TL1 gene causing the MELAS syndrome by tRNA import into mitochondria. Nucleic Acids Res 39, 8173-8186 (2011); A. S. Tulah, M. A. Birch-Machin, Stressed out mitochondria: the role of mitochondria in ageing and cancer focussing on strategies and opportunities in human skin. Mitochondrion 13, 444-453 (2013); and W. J. Koopman, P. H. Willems, J. A. Smeitink, Monogenic mitochondrial disorders. The New England journal of medicine 366, 1132-1141 (2012). Many of these diseases arise from genetic mutations within the mitochondrial DNA (mtDNA) while others are caused by mutations within the nuclear genome (nDNA) responsible for mitochondrial maintenance.
For example, mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) is a heteroplasmic and maternal inheritance mitochondrial disorder that impairs the brain, nervous, and muscle systems. More than 80% of MELAS cases are caused by the A3243G mutation in the tRNALeu gene, which regulates protein fabrication, oxygen consumption, and energy production.
Diseases and detrimental conditions may be characterized by abnormal loss of expression or underexpression of a particular protein or abnormal gain or overexpression of a
particular protein. Such diseases or detrimental conditions can be treated by upregulation or down regulation of the particular protein. Accordingly, methods of treating a disease or detrimental condition are provided where the co-localization complex as described herein associates or otherwise binds to mitochondrial DNA including a target mitochondrial nucleic acid, and the transcriptional activator of the co-localization complex upregulates expression of the target nucleic acid or the transcriptional repressor of the co-localization complex downregulates expression of the target nucleic acid. One of skill in the art will readily identify such diseases and detrimental conditions associated with mitochondrial DNA based on the present disclosure.
Mutations in mitochondrial DNA are known to result in alteration and pathological development in mitochondrial function and mitochondrial diseases, as well as cancer, diabetes, cardiovascular diseases, neurodegenerative disorders and aging (See, Alexeyev M. et al., The Maintenance of Mitochondrial DNA Integrity— Critical Analysis and Update, Cold Spring Harb Perspect Biol, (2013); 5:a012641). Accordingly, methods of treating a disease or detrimental condition are provided where foreign DNA is integrated into a mitochondrial nucleic acid sequence of a eukaryotic cell via providing to the mitochondria a guide RNA sequence complementary to a target mitochondrial nucleic acid sequence, providing to the mitochondria a donor sequence, providing to the mitochondrial a Cas9 enzyme that interacts with the guide RNA sequence and cleaves the target mitochondrial nucleic acid sequence in a site specific manner, wherein the guide RNA sequence binds to the complementary target mitochondrial nucleic acid sequence and the Cas9 enzyme cleaves the target mitochondrial nucleic acid sequence in a site specific manner; and wherein the donor sequence is integrated into the mitochondrial nucleic acid sequence.
The following examples are set forth as being representative of the present disclosure. These examples are not to be construed as limiting the scope of the present
disclosure as these and other equivalent embodiments will be apparent in view of the present disclosure, figures and accompanying claims.
EXAMPLE I
Materials and Methods
Cell lines
HT 1080 cells were initially grown and maintained in Dulbecco's modified Eagle's medium (DMEM, Invitrogen) high glucose supplemented with 10% fetal bovine serum (Invitrogen), penicillin/streptomycin (pen/strep, Invitrogen) and nonessential amino acids (Invitrogen). After AAV transduction, the HT1080 cell lines were maintained in Dulbecco's modified eagle medium with no glucose supplemented with 10 mM galactose, 10% fetal bovine serum (Invitrogen), penicillin/streptomycin (pen/strep, Invitrogen), nonessential amino acids (Invitrogen), 5 mM sodium pyruvate (Invitrogen), and 5 mM HEPES (Invitrogen). The PGP1 iPS cells were grown and maintained in mTeSRl basal medium (mTeSRl, Stemcell Technologies) with IX mTeSRl Supplement and penicillin/streptomycin (pen/strep, Invitrogen).
AAV-GFP quality control
AAV-CAG-GFP (7.4 x 1011 GC/mL) and mito-AAV-HSP-GFP (3 x 1011 GC/mL) were produced and were used to infect HT1080 seeded at 200,000 cells in a 12 well plate at 2.0 x 1010 genome copies respectively. After 3 days post virus transduction, the number of infected HT1080 cells was visualized using optical fluorescence microscopy and quantified by flow cytometry.
Transfection
HT1080 cells
A mito-AAV-Cas9 and mito-AAV-donor-RNR2T2991c-gRNA were constructed and co-transduced to target and modify the RNR2 (16sRNA) gene with a T2991C mutation. HT1080 cells transduced with mito-AAV-Cas9 and HT1080 wild type served as negative controls. The infected cells were cultured for 7 days under normal conditions to allow the mito-AAVs to dilute out of the cells (Day 0). Next, the infected cells were harvested and plated at 15,000 cells per 9.5 cm2 (1 well of a 6 well plate) and cultured in triplicates of 0, 150, 300 and 500 μg/mL CAP and harvested after 7 days.
Human PGP1 iPS cells
A mito-AAV-Cas9 and mito-AAV-donor-RNR2T2991c- TRNLl A3243G-gRNA were co- transduced into PGP1 iPS cells to target and modify both the RNR2 (16sRNA) gene with a T2991C mutation and the TRNLl (tRNALeu) gene with the A3243G mutation to create a selectable and programmable cell line to potentially model MELAS. Viable engineered HT1080 cells and HT1080 transduced with only mito-AAV-Cas9 ('Negative') cells were then seeded at 80,000 cells per 9.5 cm2 and cultured in galactose (or glucose free) media spiked with 250 μg/mL CAP. See G. Manfredi, N. Gupta, M. E. Vazquez-Memije, J. E. Sadlock, A. Spinazzola, D. C. De Vivo, E. A. Schon, Oligomycin induces a decrease in the cellular content of a pathogenic mutation in the human mitochondrial ATPase 6 gene. / Biol Chem 274, 9386-9391 (1999); and B. H. Robinson, R. Petrova-Benedict, J. R. Buncic, D. C. Wallace, Nonviability of cells with oxidative defects in galactose medium: a screening test for affected patient fibroblasts. Biochemical medicine and metabolic biology 48, 122-126 (1992) each of which are hereby incorporated by reference in its entirety.
Co-localization of mitochondria and mito-AA V-GFP
To confirm localization of mito-AAV-GFP into the mitochondria, after four days, the mitochondrion of the HT1080 cells transduced with mito-AAV-GFP were stained with nuclear and/or mitochondrial codons with MitoTracker® Deep Red FM according to manufacturer's protocol (Life Technologies). After 30 minutes incubation, the cells were rinsed with IX PBS and the transduced and stained cells were imaged using confocal microscopy to check for co-localization.
Next-generation sequencing analysis
Cell Harvest
Cells were rinsed with PBS, trypsinized, and harvested by centrifuging at 1000 x g for 4 minutes.
Next- generation sequencing and analysis
Genomic mtDNA was extracted using prepGEM (Zygem); targeted amplification of engineered mtDNA were amplified using specially designed illumine adaptor primers and prepared for NGS through PCR and analyzed according to L. Yang, M. Guell, S. Byrne, J. L. Yang, A. De Los Angeles, P. Mali, J. Aach, C. Kim-Kiselak, A. W. Briggs, X. Rios, P. Y. Huang, G. Daley, G. Church, Optimization of scarless human stem cell genome editing. Nucleic Acids Res 41, 9049-9061 (2013) hereby incorporated by refernece in its entirety.
Cell viability assay
Transduced HT1080 cells that cultured in triplicates of 0, 150, 300 and 500 μg/mL CAP and harvested after 7 days (Fig. 2B) were harvested and checked for viability using trypan blue solution, 0.4% (Life Technologies).
In vivo Retina Studies
Injections
Neonatal CD-I mice (Charles River Laboratories) were used for all injections. All animal experiments in this study were approved by the Institutional Animal Care and Use Committee at Harvard University. Subretinal viral injections were performed on male and female pups using a Femtojet Express pressure injector (Eppendorf; 920010521) and glass micropipets (Origio; C060609). For experiments where GFP was analyzed using anti-GFP immunohistochemistry, -0.1 μΐ of AAV (7xlOn GC/ml) was used, and for the FACS sorting -0.1 μΐ of AAV (2xl013 GC/ml) was used. Animals were sacrificed at p20-pl20. For the FACS sorting experiments, retinae were enzymatically dissociated with a papain mix, and gentle pipetting.
Immunohistochemistry
At p50, mouse eyeballs were fixed for 2 h in 4% PFA in PBS (pH 7.4). Retinae were then dissected out in PBS, and washed 3x in PBS for 10 minutes each. Whole retinae were blocked for 1 hour in 0.3% Triton, 0.02% SDS, 1% BSA in PBS. Samples were then incubated in primary antibody (Rabbit anti-GFP, Invitrogen, A6455, 1:500) overnight at 4°C. Next day, retinae were washed three times in lx PBS and incubated for 3 h with donkey anti- rabbit Cy3 fluorescently coupled secondary antibody (1:250). Slides were washed three times with lx PBS 15 min each, where the last wash contained DAPI (Invitrogen, D1306). Finally, retinae were mounted using Fluoromount-G (Southern Biotech, 0100-01)
EXAMPLE II
Engineered mt-AAV
Four constructs as shown in Fig. 4 were made as described above and were used to generate engineered mito-AAV: pVPl,3 and pVP2A-MTS encoding the capsid proteins, rAAV-vector with selected transgene, and pAdDeltaF6 containing auxiliary proteins. See H. Yu, R. D. Koilkonda, T. H. Chou, V. Porciatti, S. S. Ozdemir, V. Chiodo, S. L. Boye, S. E. Boye, W. W. Hauswirth, A. S. Lewin, J. Guy, Gene delivery to mitochondria by targeting modified adenoassociated virus suppresses Leber's hereditary optic neuropathy in a mouse model. Proc Natl Acad Sci U S A 109, E1238-1247 (2012) hereby incorporated by reference in its entirety.
The viral capsid protein VP2 was first engineered by fusing it with a mitochondrial targeting sequence (MTS) of the COX8 (mito-AAV) according to Proc Natl Acad Sci U S A 109, E1238-1247 (2012). To constrain the expression of the rAAV cargo in the mitochondria, five versions of rAAV-GFP were generated varying the promoters as well as the protein codon of GFP (See Fig. 1A): 1) minimal CAG promoter (CAG); 2) the minor or distal heavy- strand promoter (HSP) responsible for mRNA transcription in mitochondria; 3) HSP promoter with ATA mitochondria specific start codon; 4) HSP with AGA stop codon; and 5) HSP with AGG mitochondria specific stop codon. Notably, mitochondria specific start codon and/or stop codon constrain(s) the expression of rAAV-GFP specifically to the mitochondria, evidenced as the colocalization of GFP and mito-tracker signal. See Fig. IB. See also Fig. 5A and 5B which provide data relating to viral titer and infectionality of CAG- GFP, WT ("CAG-GFP-WT"); HSP-GFP, VP1,3, VP2-MTS ("HSP-GFP-V2-MTS"); HSP- Cas9-ST, VP1,3, VP2-MTS ("HSP-STl-MTS"); and Donor-gRNA, VP2-MTS "(Donor- Mutation-U6-TargetGene-MTS") AVV vectors in HT1080 cells. Fig. 5A shows that titer yield, which was quantified by QuickTiter™ AAV Quantitation Kit (Cell Biolabs), was not affected by packaging contents. Each virus was transduced at 2 x 1010 genome copies into HT1080 cells. As shown in Fig. 5B, flow cytometry was used to quantify number of HT1080
cells infected to compare the infectionality of engineered viral particle V.S. wild type CAG- GFP-WT. Neg refers to wild-type HT1080 cells.
Mitochondrial DNA variants C2939A or T2991C are known to confer CAP resistance. See N. Howell, I. Kubacka, Sequence analysis of mitochondrial chloramphenicol resistance mutations in Chinese hamster cells. Mammalian genome : official journal of the International Mammalian Genome Society 4, 271-275 (1993) hereby incorporated by reference in its entirety. CAP resistant cell lines were engineered by introducing specific mutations in the mitochondria genome. A mito-AAV-Cas9 and mito-AAV-donor- RNR2T2991c-gRNA were constructed and co-transduced to target and modify the RNR2 (16sRNA) gene with a T2991C mutation. See Fig. 2A, 2B, and Fig. 5A and 5B. HT1080 cells transduced with mito-AAV-Cas9 and HT1080 wild-type served as negative controls. The infected cells were cultured for 7 days under normal conditions to allow the mito-AAVs to dilute out of the cells (Day 0). Next, the infected cells were cultured in 0, 150, 300 and 500 μg/mL CAP and harvested after 7 days. NGS results confirmed introduction of the T2991C variant in HT1080 cells with 0.6 % homologous recombination (HR) efficiency (or 25 fold compared to HT1080 cells infected with only mito-AAV-Cas9). See Fig. 2C. Cellular phenotype also confirmed the introduction of the T2991C mutation into the mtDNA, that the engineered cells were 4 % viable when exposed to 300 μg/mL CAP compared to 0.79 % viability of Cas9-ST and 0.49 % viability of wild-type negative controls (ANOVA, p<0.05). See Fig. 2D and Fig. 6 A and 6B. Fig. 6 A and 6B are directed to chloramphenicol selection for engineered mitochondria which suggests a need for an optimized method to enrich for mitochondrial genome engineering in vitro. HT1080 cells were cultured in 250 μg/mL CAP galactose (glucose-free) media over 21 days to enrich for engineered T2991C mutation (green diamond). This environment, while maintaining T2991C enrichment compared to negative (Cas9 only) control (red square) (see Fig. 6A), induced evolved C2939A mutation to confer
CAP resistance in all HT1080 cells (see Fig. 6B). As shown in Fig. 6A, engineered T2991C variant drops from 0.6% efficiency to 0.1% compared to a 0.0% baseline in control cell lines over a 28-day period. Alternatively, as shown in Fig. 6B, the background of the C2939A variant increases from 0.1% to 3.3% in both engineered and control cell lines. Accordingly, the methods described herein were used to introduce a specific mitochondrial mutation in a human cell line.
A programmable cell line to model MELAS was created using the methods described herein. To this end, a mito-AAV-Cas9 and a mito-AAV-donor-RNR2T2991c- TRNL1A3243G- gRNA were co-transduced into PGP1 iPS cells to target and modify both the RNR2 (16sRNA) gene with a T2991C mutation and the TRNL1 (tRNALeu) gene with the A3243G mutation. This system was quantified at 0.3 % efficiency HR targeting efficiency of transduced cell lines (14X compared to iPSCs transduced with only mito-AAV-Cas9). See Fig. 2C.
MELAS has been known to affect the retinal ganglion cells. Methods described herein were used to edit the mitochondrial genome of the retina in vivo. Mito-AAV-CRISPR systems were engineered to introduce the A2601G on mtDNA tRNALeu, which aligns to the human A3243G variant. Mito-AAV-Cas9 and mito-AAV-donor-gRNA were co-injected into the mouse eye subretinally, along with mito-AAV-CAG-GFP to track the transduction. Retinas were dissociated and GFP positive cells were enriched and prepared for NGS to quantify the editing efficiency on the targeting site (see Fig. 3A). Notably, the efficiency of editing in vivo mitochondria was about 7% compared to 0% in the negative controls. The in vivo efficiency using infection by AAV is 10 fold higher than the efficiency observed with in vitro models (see Fig. 3B).
Illumina adapter primers used for sequencing are provided below.
I Gene I TRNL1 I
Species Mouse
Variant A2601G
Forward ACACTCTTTCCCTACACGACGCTCTTCCGATCGCGCTCTCAACCTAA primer TTTATGA (SEQ ID NO: 1)
GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTTTGAACCTCTGGG
Reverse AACAAGG (SEQ ID NO: 2)
primer
Gene TRNL1
Species Human
Variant A3243G
Forward ACACTCTTTCCCTACACGACGCTCTTCCGATCACTTCACAAAGCGCC primer TTCC (SEQ ID NO: 3)
GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTGAAGAGGAATTGA
Reverse ACCTCTGACTG (SEQ ID NO: 4)
primer
Gene RNR2
Species Human
Variant C2939A, T2991C
Forward CCCTACACGACGCTCTTCCGATCCAATAACTTGACCAACGGAACA
primer (SEQ ID NO: 5)
Reverse GTTCAGACGTGTGCTCTTCCGATCTACCTTTAATAGCGGCTGCAC primer (SEQ ID NO: 6)
Plasmid sequences are provided below as indicated.
Mito-pAAV-GFP
CCCACCCCCAATTTTGTATTTATTTATTTTTTAATTATTTTGTGCAGCGATGGGGGCGGGGG GGGGGGGGGGGCGCGCGCCAGGCGGGGCGGGGCGGGGCGAGGGGCGGGGCGGGGCGAGGCGG AGAGGTGCGGCGGCAGCCAATCAGAGCGGCGCGCTCCGAAAGTTTCCTTTTATGGCGAGGCG GCGGCGGCGGCGGCCCTATAAAAAGCGAAGCGCGCGGCGGGCGGGAGTCGCTGCGACGCTGC CTTCGCCCCGTGCCCCGCTCCGCCGCCGCCTCGCGCCGCCCGCCCCGGCTCTGACTGACCGC GTTACTCCCACAGGTGAGCGGGCGGGACGGCCCTTCTCCTCCGGGCTGTAATTAGCGCTTGG TTTAATGACGGCTTGTTTCTTTTCTGTGGCTGCGTGAAAGCCTTGAGGGGCTCCGGGAGGGC CCTTTGTGCGGGGGGAGCGGCTCGGGGCTGTCCGCGGGGGGACGGCTGCCTTCGGGGGGGAC GGGGCAGGGCGGGGTTCGGCTTCTGGCGTGTGACCGGCGGCTCTAGAGCCTCTGCTAACCAT GTTCATGCCTTCTTCTTTTTCCTACAGCTCCTGGGCAACGTGCTGGTTATTGTGCTGTCTCA TCATTTTGGCAAAGAATTGGATCGGGATCCCCGGGTACCGGTCGCCACCATGGTGAGCAAGG GCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGC CACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAA GTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCC
GCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAA GACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCA TCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCAC AACGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCA CAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCCATCGGCG ACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCGCCCTGAGCAAAGAC CCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCT CGGCATGGACGAGCTGTACAAG (SEQ ID NO: 7) pHSP-Cas9-STl cassette sequence
CCGCTGCTAACCCCATACCCCGAACCAACCAAACCCCAAAGACACCCCCCgccaccATGAGC GACCTGGTGCTGGGCCTGGACATCGGCATCGGCAGCGTGGGCGTGGGCATCCTGAACAAGGT GACCGGCGAGATCATCCACAAGAACAGTCGCATCTTCCCTGCTGCTCAGGCTGAGAACAACC TGGTGCGCCGCACCAACCGCCAGGGTCGCCGGCTTGCTCGCCGCAAGAAGCACCGGCGCGTG CGCCTGAACCGCCTGTTCGAGGAGAGCGGCCTGATCACCGACTTCACCAAGATCAGCATCAA CCTGAACCCCTACCAGCTGCGCGTGAAGGGCCTGACCGACGAGCTGAGCAACGAGGAGCTGT TCATCGCCCTGAAGAACATGGTGAAGCACCGCGGCATCAGCTACCTGGACGACGCCAGCGAC GACGGCAACAGCAGCGTGGGCGACTACGCCCAGATCGTGAAGGAGAACAGCAAGCAGCTGGA GACCAAGACCCCCGGCCAGATCCAGCTGGAGCGCTACCAGACCTACGGCCAGCTGCGCGGCG ACTTCACCGTGGAGAAGGACGGCAAGAAGCACCGCCTGATCAACGTGTTCCCCACCAGCGCC TACCGCAGCGAGGCCCTGCGCATCCTGCAGACCCAGCAGGAGTTCAACCCCCAGATCACCGA CGAGTTCATCAACCGCTACCTGGAGATCCTGACCGGCAAGCGCAAGTACTACCACGGCCCCG GCAACGAGAAGAGCCGCACCGACTACGGCCGCTACCGCACCAGCGGCGAGACCCTGGACAAC ATCTTCGGCATCCTGATCGGCAAGTGCACCTTCTACCCCGACGAGTTCCGCGCCGCCAAGGC CAGCTACACCGCCCAGGAGTTCAACCTGCTGAACGACCTGAACAACCTGACCGTGCCCACCG AGACCAAGAAGCTGAGCAAGGAGCAGAAGAACCAGATCATCAACTACGTGAAGAACGAGAAG GCCATGGGCCCCGCCAAGCTGTTCAAGTACATCGCCAAGCTGCTGAGCTGCGACGTGGCCGA CATCAAGGGCTACCGCATCGACAAGAGCGGCAAGGCCGAGATCCACACCTTCGAGGCCTACC GCAAGATGAAGACCCTGGAGACCCTGGACATCGAGCAGATGGACCGCGAGACCCTGGACAAG CTGGCCTACGTGCTGACCCTGAACACCGAGCGCGAGGGCATCCAGGAGGCCCTGGAGCACGA GTTCGCCGACGGCAGCTTCAGCCAGAAGCAGGTGGACGAGCTGGTGCAGTTCCGCAAGGCCA ACAGCAGCATCTTCGGCAAGGGCTGGCACAACTTCAGCGTGAAGCTGATGATGGAGCTGATC CCCGAGCTGTACGAGACCAGCGAGGAGCAGATGACCATCCTGACCCGCCTGGGCAAGCAGAA GACCACCAGCAGCAGCAACAAGACCAAGTACATCGACGAGAAGCTGCTGACCGAGGAGATCT ACAACCCCGTGGTGGCCAAGAGCGTGCGCCAGGCCATCAAGATCGTGAACGCCGCCATCAAG GAGTACGGCGACTTCGACAACATCGTGATCGAGATGGCCCGCGAGACCAACGAGGACGACGA GAAGAAGGCCATCCAGAAGATCCAGAAGGCCAACAAGGACGAGAAGGACGCCGCCATGCTGA AGGCCGCCAACCAGTACAACGGCAAGGCCGAGCTGCCCCACAGCGTGTTCCACGGCCACAAG CAGCTGGCCACCAAGATCCGCCTGTGGCACCAGCAGGGCGAGCGCTGCCTGTACACCGGCAA GACCATCAGCATCCACGACCTGATCAACAACAGCAACCAGTTCGAGGTGGACCACATCCTGC CCCTGAGCATCACCTTCGACGACAGCCTGGCCAACAAGGTGCTGGTGTACGCCACCGCCAAC CAGGAGAAGGGCCAGCGCACCCCCTACCAGGCCCTGGACAGCATGGACGACGCCTGGAGCTT CCGCGAGCTGAAGGCCTTCGTGCGCGAGAGCAAGACCCTGAGCAACAAGAAGAAGGAGTACC TGCTGACCGAGGAGGACATCAGCAAGTTCGACGTGCGCAAGAAGTTCATCGAGCGCAACCTG GTGGACACCCGCTACGCCAGCCGCGTGGTGCTGAACGCCCTGCAGGAGCACTTCCGCGCCCA CAAGATCGACACCAAGGTGAGCGTGGTGCGCGGCCAGTTCACCAGCCAGCTGCGCCGCCACT GGGGCATCGAGAAGACCCGCGACACCTACCACCACCACGCCGTGGACGCCCTGATCATTGCG GCTTCTAGCCAGCTGAACCTGTGGAAGAAGCAGAAGAACACCCTGGTGAGCTACAGCGAGGA CCAGCTGCTGGACATCGAGACCGGCGAGCTGATCAGCGACGACGAGTACAAGGAGAGCGTGT
TCAAGGCCCCCTACCAGCACTTCGTGGACACCCTGAAGAGCAAGGAGTTCGAGGACAGCATC CTGTTCAGCTACCAGGTGGACAGCAAGTTCAACCGCAAGATCAGCGACGCCACCATCTACGC CACCCGCCAGGCCAAGGTGGGCAAGGACAAGGCCGACGAGACCTACGTGCTGGGCAAGATCA AGGACATCTACACCCAGGACGGCTACGACGCCTTCATGAAGATCTACAAGAAGGACAAGAGC AAGTTCCTGATGTACCGCCACGACCCCCAGACCTTCGAGAAGGTGATCGAGCCCATCCTGGA GAACTACCCCAACAAGCAGATCAACGATAAAGGCAAGGAGGTGCCCTGCAACCCCTTCCTGA AGTACAAGGAGGAGCACGGCTACATCCGCAAGTACAGCAAGAAGGGCAACGGCCCCGAGATC AAGAGCCTGAAGTACTACGACAGCAAGCTGGGCAACCACATCGACATCACCCCCAAGGACAG CAACAACAAGGTGGTGCTGCAGAGCGTGAGCCCCTGGCGCGCCGACGTGTACTTCAACAAGA CCACCGGCAAGTACGAGATCCTGGGCCTGAAGTACGCCGACCTGCAGTTTGATAAGGGCACC GGCACCTACAAGATCAGCCAGGAGAAGTACAACGACATCAAGAAGAAGGAGGGCGTGGACAG CGACAGCGAGTTCAAGTTCACCCTGTACAAGAACGACCTTCTGCTGGTGAAGGACACCGAGA CCAAGGAGCAACAGCTGTTCCGCTTCCTGAGCCGCACCATGCCCAAGCAGAAGCACTACGTG GAGCTGAAGCCCTACGACAAGCAGAAGTTCGAGGGCGGCGAGGCCCTGATCAAGGTGCTGGG CAACGTGGCCAACAGCGGCCAGTGCAAGAAGGGCCTGGGCAAGAGCAACATCAGCATCTACA AGGTGCGCACCGACGTGCTGGGCAACCAGCACATCATCAAGAACGAGGGCGACAAGCCCAAG CTGGACTTCtaa (SEQ ID NO: 8)
Mito-pAAV-Donor-RNR2r299JC-TRNLlA3243G-gRNA
AGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCATTAATGCAGCTGCGCG CTCGCTCGCTCACTGAGGCCGCCCGGGCAAAGCCCGGGCGTCGGGCGACCTTTGGTCGCCCG GCCTCAGTGAGCGAGCGAGCGCGCAGAGAGGGAGTGGCCAACTCCATCACTAGGGGTTCCTT GTAGTTAATGATTAACCCGCCATGCTACTTATCTACGTAGCCATGCTCTAGGAAGATCGTAC CATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGT CAATGGGTGGACTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCC AAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACA TGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATG GT TAGCTGGTTGTCCAAGATAGAATCTTAGTTCAACTTTAAATTTGCCCACAGAACCCTCTA AATCCCCTTGTAAATTTAACTGTTAGTCCAAAGAGGAACAGCTCTTTGGACACTAGGAAAAA ACCTTGTAGAGAGAGTAAAAAATTTAACACCCATAGTAGGCCTAAAAGCAGCCACCAATTAA GAAAGCGTTCAAGCTCAACACCCACTACCTAAAAAATCCCAAACATATAACTGAACTCCTCA CACCCAATTGGACCAATCTATCACCCTATAGAAGAACTAATGTTAGTATAAGTAACATGAAA ACATTCTCCTCCGCATAAGCCTGCGTCAGATTAAAACACTGAACTGACAATTAACAGCCCAA TATCTACAATCAACCAACAAGTCATTATTACCCTCACTGTCAACCCAACACAGGCATGCTCA TAAGGAAAGGTTAAAAAAAGTAAAAGGAACTCGGCAAATCTTACCCCGCCTGTTTACCAAAA ACATCACCTCTAGCATCACCAGTATTAGAGGCACCGCCTGCCCAGTGACACATGTTTAACGG CCGCGGTACCCTAACCGTGCAAAGGTAGCATAATCACTTGTTCCTTAAATAGGGACCTGTAT GAATGGCTCCACGAGGGTTCAGCTGTCTCTTACTTTTAACCAGTGAAATTGACCTGCCCGTG AAGAGGCGGGCATAACACAGCAAGACGAGAAGACCCTATGGAGCTTTAATTTATTAATGCAA ACAGTACCTAACAAACCCACAGGTCCTAAACTACCAAACCTGCATTAAAAATTTCGGTTGGG GCGACCTCGGAGCAGAACCCAACCTCCGAGCAGTACATGCTAAGACTTCACCAGTCAAAGCG AACTACTATACTCAATTGATCCAATAACTTGACCAACGGAACAAGTTACCCTAGGGATAACA GCGCAATCCTATTCTAGAGTCCATATCAACAATAGGGTTTACGACCTCGACGTTGGATCAGG ACATCCCGATGGTGCAGCCGCTATTAAAGGTTCGTTTGTTCAACGATTAAAGTCCTACGTGA TCTGAGTTCAGACCGGAGTAATCCAGGTCGGTTTCTATCTACNTTCAAATTCCTCCCTGTAC GAAAGGACAAGAGAAATAAGGCCTACTTCACAAAGCGCCTTCCCCCGTAAATGATATCATCT CAACTTAGTATTATACCCACACCCACCCAAGAACAGGGTTTGTTAAGATGGCAGGGCCCGGT AATCGCATAAAACTTAAAACTTTACAGTCAGAGGTTCAATTCCTCTTCTTAACAACATACCC ATGGCCAACCTCCTACTCCTCATTGTACCCATTCTAATCGCAATGGCATTCCTAATGCTTAC CGAACGAAAAATTCTAGGCTATATACAACTACGCAAAGGCCCCAACGTTGTAGGCCCCTACG GGCTACTACAACCCTTCGCTGACGCCATAAAACTCTTCACCAAAGAGCCCCTAAAACCCGCC
ACATCTACCATCACCCTCTACATCACCGCCCCGACCTTAGCTCTCACCATCGCTCTTCTACT ATGAACCCCCCTCCCCATACCCAACCCCCTGGTCAACCTCAACCTAGGCCTCCTATTTATTC TAGCCACCTCTAGCCTAGCCGTTTACTCAATCCTCTGATCAGGGTGAGCATCAAACTCAAAC TACGCCCTGATCGGCGCACTGCGAGCAGTAGCCCAAACAATCTCATATGAAGTCACCCTAGC CATCATTCTACTATCAACATTACTAATAAGTGGCTCCTTTAACCTCTCCACCCTTATCACAA CACAAGAACACCTCTGATTACTCCTGCCATCATGACCCTTGGCCATAATATGATTTATCTCC ACACTAGCAGAGACCAACCGAACCCCCTTCGACCTTGCCGAAGGGGAGTCCGAACTAGTCTC AGGCTTCAACATCGAATACGCCGCAGGCCCCTTCGCCCTATTCTTCATAGCCGAATACACAA ACATTATTATAATAAACACCCTCACCACTACAATCTTCCTAGGAACAACAATTAGCGCTTGG TTTAATGACGGCTTGTTTCTTTTCTGTACAAAAAAGCAGGCTTTAAAGGAACCAATTCAGTC GACTGGATCCGGTACCAAGGTCGGGCAGGAAGAGGGCCTATTTCCCATGATTCCTTCATATT T GCAT AT AC GAT AC AAGGC T GT T AGAGAGAT AAT T AGAAT T AAT T T GAC T GT AAACACAAAG ATATTAGTACAAAATACGTGACGTAGAAAGTAATAATTTCTTGGGTAGTTTGCAGTTTTAAA AT TAT GT T T T AAAAT GGAC TAT CAT AT GC T T ACC GT AAC T T GAAAGT AT T T C GAT T T CT T GG CTTTATATATCTTGTGGAAAGGACGAAACACCGGATAACAGCGCAATCCTATTGTTTTTGTA CTCTCAGAAATGCAGAAGCTACAAAGATAAGGCTTCATGCCGAAATCAACACCCTGTCATTT TATGGCAGGGTGTTTTTTTGACCTTGCCGAAGGGGAGTCCGAACTAGTCTCAGATGTACAAA AAAGCAGGCTTTAAAGGAACCAATTCAGTCGACTGGATCCGGTACCAAGGTCGGGCAGGAAG AGGGCCTATTTCCCATGATTCCTTCATATTTGCATATACGATACAAGGCTGTTAGAGAGATA AT TAGAAT T AAT T T GACT GT AAAC ACAAAGAT AT T AGT ACAAAAT ACGT GAC GT AGAAAGT A AT AAT T T CT T GGGT AGT T T GCAGT T T T AAAAT TAT GT T T T AAAAT GGAC TAT CAT AT GC T T A CCGTAACTTGAAAGTATTTCGATTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACC GTTTACGACCTCGATGTTGGAGTTTTTGTACTCTCAGAAATGCAGAAGCTACAAAGATAAGG CTTCATGCCGAAATCAACACCCTGTCATTTTATGGCAGGGTGTTTTTTTAAGTTAACAACAA CAATTGCATTCATTTTATGTTTCAGGTTCAGGGGGAGATGTGGGAGGTTTTTTAAAGCAAGT AAAACCTCTACAAATGTGGTAAAATCGATAAGGATCTTCCTAGAGCATGGCTACGTAGATAA GTAGCATGGCGGGTTAATCATTAACTACAAGGAACCCCTAGTGATGGAGTTGGCCACTCCCT CTCTGCGCGCTCGCTCGCTCACTGAGGCCGGGCGACCAAAGGTCGCCCGACGCCCGGGCTTT GCCCGGGCGGCCTCAGTGAGCGAGCGAGCGCGCAGCCTTAATTAACCTAATTCACTGGCCGT CGTTTTACAACGTCGTGACTGGGAAAACCCTGGCGTTACCCAACTTAATCGCCTTGCAGCAC ATCCCCCTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAG TTGCGCAGCCTGAATGGCGAATGGGACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGT GGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGCTT TCTTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGGGCTC CCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTAGGGTGA TGGTTC ACGT AGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGT CCA CGTTCTTTAATAGTGGACTCTTGTTCCAAACTGGAACAACACTCAACCCTATCTCGGTCTAT TCTTTTGATTTATAAGGGATTTTGCCGATTTCGGCCTATTGGTTAAAAAATGAGCTGATTTA ACAAAAATTTAACGCGAATTTTAACAAAATATTAACGCTTACAATTTAGGTGGCACTTTTCG GGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGC TCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATT CAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCA CCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACA TCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCA ATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCA AGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCA CAGAAAAGCATCTTACGGATGGCATGAC AGT AAG AGAAT TATGCAGTGCTGC CAT AACCATG AGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGC TTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATG AAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGTAGCAATGGCAACAACGTTGCGC AAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGA
GGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTG
ATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGT
AAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAA
TAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTT
ACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAG
ATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTC
AGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCT
GCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCA
ACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTAGT
GTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGC
TAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCA
AGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCC
CAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCG
CCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGA
GAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCG
CCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAA
ACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTC
TTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATAC
CGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAG ( SEQ
ID NO: 9)
Claims
1. A method of altering mitochondrial DNA of a eukaryotic cell comprising providing to the eukaryotic cell a first vector including a first nucleic acid sequence encoding a guide RNA sequence complementary to a target mitochondrial nucleic acid sequence,
providing to the eukaryotic cell a second vector including a second nucleic acid sequence encoding a Cas9 enzyme that interacts with the guide RNA sequence and cleaves the target mitochondrial nucleic acid sequence in a site specific manner,
wherein the first vector delivers the first nucleic acid sequence into the mitochondria of the eukaryotic cell, wherein the first nucleic acid sequence is expressed,
wherein the second vector delivers the second nucleic acid sequence into the mitochondria of the eukaryotic cell, wherein the second nucleic acid sequence is expressed, wherein the guide RNA sequence binds to the complementary target mitochondrial nucleic acid sequence and the Cas9 enzyme cleaves the target mitochondrial nucleic acid sequence in a site specific manner.
2. The method of claim 1 wherein the first vector is a mito-specific adeno- associated virus.
3. The method of claim 1 wherein the second vector is a mito-specific adeno- associated virus.
4. The method of claim 1 wherein the first vector is a mito-specific adeno- associated virus and the second vector is a mito-specific adeno-associated virus.
5. The method of claim 1 further including the step of providing a donor sequence into the mitochondria and wherein the donor sequence is inserted into the mitochondrial DNA.
6. The method of claim 1 wherein the donor nucleic acid sequence and the gRNA are connected.
7. The method of claim 1 wherein the first vector includes a third nucleic acid sequence encoding a donor nucleic acid sequence.
8. (Original) The method of claim 1 wherein the eukaryotic cell is a yeast cell, a plant cell or a mammalian cell.
9. (Original) The method or claim 1 wherein the eukaryotic cell is a human cell.
10. (Original) The method of claim 1 wherein a plurality of guide RNAs are provided into the mitochondria that are complementary to different target mitochondrial nucleic acid sequences and the Cas9 enzyme cleaves the different target mitochondrial nucleic acid sequences in a site specific manner.
11. A construct including a mito-AAV and a nucleic acid encoding a Cas9 protein.
12. A construct including a mito-AAV and a nucleic acid encoding a gRNA.
13. A construct including a mito-AAV, a donor nucleic acid sequence and a nucleic acid sequence encoding a gRNA.
14. A method for systemically altering mitochondrial DNA within a eukaryotic cell within tissue comprising delivering into the tissue
a first vector including a first nucleic acid sequence encoding a guide RNA sequence complementary to a target mitochondrial nucleic acid sequence,
a second vector including a second nucleic acid sequence encoding a Cas9 enzyme that interacts with the guide RNA sequence and cleaves the target mitochondrial nucleic acid sequence in a site specific manner,
wherein the first vector delivers the first nucleic acid sequence into the mitochondria of the eukaryotic cell, wherein the first nucleic acid sequence is expressed,
wherein the second vector delivers the second nucleic acid sequence into the mitochondria of the eukaryotic cell, wherein the second nucleic acid sequence is expressed, wherein the guide RNA sequence binds to the complementary target mitochondrial nucleic acid sequence and the Cas9 enzyme cleaves the target mitochondrial nucleic acid sequence in a site specific manner.
15. A eukaryotic cell wherein mitochondria therein include
a nucleic acid encoding a guide RNA sequence complementary to a target mitochondrial nucleic acid sequence,
a nucleic acid encoding a Cas9 enzyme that interacts with the guide RNA sequence and cleaves the target mitochondrial nucleic acid sequence in a site specific manner,
wherein the mitochondria expresses the guide RNA and the Cas9 enzyme, the guide RNA binds to the complementary target nucleic acid and the Cas9 enzyme cleaves the target mitochondrial nucleic acid in a site specific manner.
16. The eukaryotic cell of claim 15 wherein the eukaryotic cell is a yeast cell, a plant cell or a mammalian cell.
17. The eukaryotic cell of claim 15 wherein the eukaryotic cell is a human cell.
18. The eukaryotic cell of claim 15 wherein the mitochondria further include a plurality of nucleic acids encoding a plurality of guide RNA sequences complementary to different target mitochondrial nucleic acid sequences.
19. A method of integrating foreign DNA into a mitochondrial nucleic acid sequence of a eukaryotic cell comprising
providing to the mitochondria a guide RNA sequence complementary to a target mitochondrial nucleic acid sequence
providing to the mitochondria a donor sequence,
providing to the mitochondrial a Cas9 enzyme that interacts with the guide RNA sequence and cleaves the target mitochondrial nucleic acid sequence in a site specific manner, wherein the guide RNA sequence binds to the complementary target mitochondrial nucleic acid sequence and the Cas9 enzyme cleaves the target mitochondrial nucleic acid sequence in a site specific manner; and
wherein the donor sequence is integrated into the mitochondrial nucleic acid sequence.
20. The method of claim 19 wherein the donor nucleic acid is integrated into the mitochondrial nucleic acid sequence by homologous recombination.
21. The method of claim 19
wherein the guide RNA is provided to the mitochondria by introducing into the mitochondria a nucleic acid encoding the guide RNA,
wherein the donor nucleic acid sequence is provided to the mitochondria by introducing into the mitochondria a nucleic acid encoding the donor nucleic acid sequence, wherein the Cas9 enzyme is provided to the mitochondria by introducing into the mitochondria a nucleic acid encoding the Cas9 enzyme, and
wherein the guide RNA and the Cas9 proteins are expressed within the mitochondria.
22. The method of claim 19
wherein the guide RNA is provided to the mitochondria by a mito-adeno-associated virus including a nucleic acid encoding the guide RNA,
wherein the donor nucleic acid sequence is provided to the mitochondria by a mito- adeno-associated virus including the donor nucleic acid sequence,
wherein the Cas9 enzyme is provided to the mitochondria by a mito-adeno-associated virus including a nucleic acid encoding the Cas9 enzyme, and
wherein the guide RNA and the Cas9 proteins are expressed within the mitochondria.
23. The method of claim 19 wherein the cell is a yeast cell, a plant cell or a mammalian cell.
24. The method or claim 19 wherein the cell is a human cell.
25. A method of modulating expression of a target mitochondrial nucleic acid within a mitochondria of a eukaryotic cell comprising
providing into the mitochondria a guide RNA complementary to the target mitochondrial nucleic acid sequence,
providing into the mitochondria a Cas9 protein having inactive nuclease domains, wherein the Cas9 protein having inactive nuclease domains includes a transcriptional activator or repressor domain connected thereto for modulating target mitochondrial nucleic acid expression in vivo,
wherein the guide RNA and the Cas9 protein including the transcriptional activator or repressor domain co-localize at the target mitochondrial nucleic acid sequence and wherein the transcriptional activator or repressor domain modulates expression of the target mitochondrial nucleic acid sequence.
26. The method of claim 25
wherein the guide RNA is provided to the mitochondria by introducing into the mitochondria a nucleic acid encoding the guide RNA,
wherein the Cas9 protein including the transcriptional activator or repressor domain is provided into the cell by introducing into the mitochondria a nucleic acid encoding the Cas9 protein including the transcriptional activator or repressor domain, and
wherein the cell expresses the guide RNA and the Cas9 protein including the transcriptional activator or repressor domain.
27. The method of claim 25 wherein the cell is a eukaryotic cell.
28. The method of claim 25 wherein the cell is a yeast cell, a plant cell or a mammalian cell.
29. The method or claim 25 wherein the cell is a human cell.
30. A method of modulating expression of a target mitochondrial nucleic acid within a mitochondria of a eukaryotic cell comprising
providing into the mitochondria a guide RNA complementary to the target mitochondrial nucleic acid sequence, with the guide RNA having a transcriptional activator or repressor domain connected thereto for modulating target mitochondrial nucleic acid expression in vivo,
providing into the mitochondria a Cas9 protein having inactive nuclease domains, wherein the guide RNA and the Cas9 protein co-localize at the target mitochondrial nucleic acid sequence and wherein the transcriptional activator or repressor domain modulates expression of the target mitochondrial nucleic acid sequence.
31. The method of claim 30
wherein the guide RNA is provided to the mitochondria by introducing into the mitochondria a nucleic acid encoding the guide RNA and the transcriptional activator or repressor domain,
wherein the Cas9 protein is provided into the cell by introducing into the mitochondria a nucleic acid encoding the Cas9 protein, and
wherein the cell expresses the guide RNA and the Cas9 protein including the transcriptional activator or repressor domain.
32. The method of claim 30 wherein the cell is a eukaryotic cell.
33. The method of claim 30 wherein the cell is a yeast cell, a plant cell or a mammalian cell.
34. The method or claim 30 wherein the cell is a human cell.
35. A method of modulating expression of a target mitochondrial nucleic acid within a mitochondria of a eukaryotic cell comprising
providing into the mitochondria a guide RNA complementary to the target mitochondrial nucleic acid sequence,
providing into the mitochondria a Cas9 protein having inactive nuclease domains, providing into the mitochondria a transcriptional activator or repressor domain for modulating target mitochondrial nucleic acid expression in vivo, wherein the transcriptional activator or repressor domain becomes attached to either the guide RNA or the Cas9 protein, wherein the guide RNA and the Cas9 protein co-localize at the target mitochondrial nucleic acid sequence and wherein the transcriptional activator or repressor domain modulates expression of the target mitochondrial nucleic acid sequence.
36. The method of claim 35
wherein the guide RNA is provided to the mitochondria by introducing into the mitochondria a nucleic acid encoding the guide RNA,
wherein the Cas9 protein is provided into the cell by introducing into the mitochondria a nucleic acid encoding the Cas9 protein,
wherein the transcriptional activator or repressor domain is provided into the cell by introducing into the mitochondria a nucleic acid encoding the transcriptional activator or repressor domain, and
wherein the cell expresses the guide RNA and the Cas9 protein.
37. The method of claim 35 wherein the cell is a eukaryotic cell.
38. The method of claim 35 wherein the cell is a yeast cell, a plant cell or a mammalian cell.
39. The method or claim 35 wherein the cell is a human cell.
40. A eukaryotic cell comprising engineered mitochondria wherein the engineered mitochondria comprising
a guide RNA sequence complementary to a target mitochondrial nucleic acid sequence,
a donor nucleic acid sequence, and
a Cas9 enzyme that interacts with the guide RNA sequence and cleaves the target mitochondrial nucleic acid sequence in a site specific manner,
wherein the guide RNA sequence binds to the complementary target mitochondrial nucleic acid sequence and the Cas9 enzyme cleaves the target mitochondrial nucleic acid sequence in a site specific manner; and
wherein the donor sequence is integrated into the mitochondrial nucleic acid sequence.
41. The eukaryotic cell of claim 40 wherein the donor nucleic acid is integrated into the mitochondrial nucleic acid sequence by homologous recombination.
42. The eukaryotic cell of claim 40
wherein the guide RNA is provided to the mitochondria by introducing into the mitochondria a nucleic acid encoding the guide RNA,
wherein the donor nucleic acid sequence is provided to the mitochondria by introducing into the mitochondria a nucleic acid encoding the donor nucleic acid sequence, wherein the Cas9 enzyme is provided to the mitochondria by introducing into the mitochondria a nucleic acid encoding the Cas9 enzyme, and
wherein the guide RNA and the Cas9 proteins are expressed within the mitochondria.
43. The eukaryotic cell of claim 40
wherein the guide RNA is provided to the mitochondria by a mito-adeno-associated virus including a nucleic acid encoding the guide RNA,
wherein the donor nucleic acid sequence is provided to the mitochondria by a mito- adeno-associated virus including the donor nucleic acid sequence,
wherein the Cas9 enzyme is provided to the mitochondria by a mito-adeno-associated virus including a nucleic acid encoding the Cas9 enzyme, and
wherein the guide RNA and the Cas9 proteins are expressed within the mitochondria.
44. The eukaryotic cell of claim 40 wherein the cell is a yeast cell, a plant cell or a mammalian cell.
45. The eukaryotic cell of claim 40 wherein the cell is a human cell.
46. A eukaryotic cell comprising engineered mitochondria wherein the engineered mitochondria comprising
a guide RNA complementary to the target mitochondrial nucleic acid sequence,
a Cas9 protein having inactive nuclease domains,
wherein the Cas9 protein having inactive nuclease domains includes a transcriptional activator or repressor domain connected thereto for modulating target mitochondrial nucleic acid expression in vivo,
wherein the guide RNA and the Cas9 protein including the transcriptional activator or repressor domain co-localize at the target mitochondrial nucleic acid sequence and wherein the transcriptional activator or repressor domain modulates expression of the target mitochondrial nucleic acid sequence.
47. The eukaryotic cell of claim 46
wherein the guide RNA is provided to the mitochondria by introducing into the mitochondria a nucleic acid encoding the guide RNA,
wherein the Cas9 protein including the transcriptional activator or repressor domain is provided into the cell by introducing into the mitochondria a nucleic acid encoding the Cas9 protein including the transcriptional activator or repressor domain, and
wherein the cell expresses the guide RNA and the Cas9 protein including the transcriptional activator or repressor domain.
48. The eukaryotic cell of claim 46 wherein the cell is a eukaryotic cell.
49. The eukaryotic cell of claim 46 wherein the cell is a yeast cell, a plant cell or a mammalian cell.
50. The eukaryotic cell of claim 46 wherein the cell is a human cell.
51. A eukaryotic cell comprising engineered mitochondria wherein the engineered mitochondria comprising
a guide RNA complementary to the target mitochondrial nucleic acid sequence, with the guide RNA having a transcriptional activator or repressor domain connected thereto for modulating target mitochondrial nucleic acid expression in vivo,
a Cas9 protein having inactive nuclease domains,
wherein the guide RNA and the Cas9 protein co-localize at the target mitochondrial nucleic acid sequence and wherein the transcriptional activator or repressor domain modulates expression of the target mitochondrial nucleic acid sequence.
52. The eukaryotic cell of claim 51
wherein the guide RNA is provided to the mitochondria by introducing into the mitochondria a nucleic acid encoding the guide RNA and the transcriptional activator or repressor domain,
wherein the Cas9 protein is provided into the cell by introducing into the mitochondria a nucleic acid encoding the Cas9 protein, and
wherein the cell expresses the guide RNA and the Cas9 protein including the transcriptional activator or repressor domain.
53. The eukaryotic cell of claim 46 wherein the cell is a eukaryotic cell.
54. The eukaryotic cell of claim 46 wherein the cell is a yeast cell, a plant cell or a mammalian cell.
55. The eukaryotic cell of claim 46 wherein the cell is a human cell.
56. A eukaryotic cell comprising engineered mitochondria wherein the engineered mitochondria comprising
a guide RNA complementary to the target mitochondrial nucleic acid sequence, a Cas9 protein having inactive nuclease domains,
a transcriptional activator or repressor domain for modulating target mitochondrial nucleic acid expression in vivo, wherein the transcriptional activator or repressor domain becomes attached to either the guide RNA or the Cas9 protein,
wherein the guide RNA and the Cas9 protein co-localize at the target mitochondrial nucleic acid sequence and wherein the transcriptional activator or repressor domain modulates expression of the target mitochondrial nucleic acid sequence.
57. The eukaryotic cell of claim 56
wherein the guide RNA is provided to the mitochondria by introducing into the mitochondria a nucleic acid encoding the guide RNA,
wherein the Cas9 protein is provided into the cell by introducing into the mitochondria a nucleic acid encoding the Cas9 protein,
wherein the transcriptional activator or repressor domain is provided into the cell by introducing into the mitochondria a nucleic acid encoding the transcriptional activator or repressor domain, and
wherein the cell expresses the guide RNA and the Cas9 protein.
The eukaryotic cell of claim 56 wherein the cell is a eukaryotic cell.
59. The eukaryotic cell of claim 56 wherein the cell is a yeast cell, a plant cell or a mammalian cell.
The eukaryotic cell of claim 56 wherein the cell is a human cell.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/075,247 US11208652B2 (en) | 2016-02-04 | 2017-02-02 | Mitochondrial genome editing and regulation |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662291040P | 2016-02-04 | 2016-02-04 | |
US62/291,040 | 2016-02-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017136520A1 true WO2017136520A1 (en) | 2017-08-10 |
Family
ID=59500240
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2017/016168 WO2017136520A1 (en) | 2016-02-04 | 2017-02-02 | Mitochondrial genome editing and regulation |
Country Status (2)
Country | Link |
---|---|
US (1) | US11208652B2 (en) |
WO (1) | WO2017136520A1 (en) |
Cited By (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9999671B2 (en) | 2013-09-06 | 2018-06-19 | President And Fellows Of Harvard College | Delivery of negatively charged proteins using cationic lipids |
US10113163B2 (en) | 2016-08-03 | 2018-10-30 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
US10167457B2 (en) | 2015-10-23 | 2019-01-01 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
WO2019040645A1 (en) * | 2017-08-22 | 2019-02-28 | Napigen, Inc. | Organelle genome modification using polynucleotide guided endonuclease |
US10323236B2 (en) | 2011-07-22 | 2019-06-18 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
US10465176B2 (en) | 2013-12-12 | 2019-11-05 | President And Fellows Of Harvard College | Cas variants for gene editing |
US10508298B2 (en) | 2013-08-09 | 2019-12-17 | President And Fellows Of Harvard College | Methods for identifying a target site of a CAS9 nuclease |
US10597679B2 (en) | 2013-09-06 | 2020-03-24 | President And Fellows Of Harvard College | Switchable Cas9 nucleases and uses thereof |
US10704062B2 (en) | 2014-07-30 | 2020-07-07 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
WO2020159470A1 (en) * | 2019-01-28 | 2020-08-06 | Mayo Foundation For Medical Education And Research | Mitochondrial genome editing methods |
US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
US10858639B2 (en) | 2013-09-06 | 2020-12-08 | President And Fellows Of Harvard College | CAS9 variants and uses thereof |
CN112251468A (en) * | 2020-10-22 | 2021-01-22 | 钟刚 | Mitochondrial targeted gene editing complex, preparation method and application thereof, and mitochondrial genome editing method |
WO2021022046A1 (en) * | 2019-07-31 | 2021-02-04 | Bioskryb, Inc. | Genetic mutational analysis |
US11046948B2 (en) | 2013-08-22 | 2021-06-29 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
US11268082B2 (en) | 2017-03-23 | 2022-03-08 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable DNA binding proteins |
US11306324B2 (en) | 2016-10-14 | 2022-04-19 | President And Fellows Of Harvard College | AAV delivery of nucleobase editors |
US11319532B2 (en) | 2017-08-30 | 2022-05-03 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
US11447770B1 (en) | 2019-03-19 | 2022-09-20 | The Broad Institute, Inc. | Methods and compositions for prime editing nucleotide sequences |
US11542496B2 (en) | 2017-03-10 | 2023-01-03 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
US11661590B2 (en) | 2016-08-09 | 2023-05-30 | President And Fellows Of Harvard College | Programmable CAS9-recombinase fusion proteins and uses thereof |
US11732274B2 (en) | 2017-07-28 | 2023-08-22 | President And Fellows Of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE) |
US11795443B2 (en) | 2017-10-16 | 2023-10-24 | The Broad Institute, Inc. | Uses of adenosine base editors |
US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
US11912985B2 (en) | 2020-05-08 | 2024-02-27 | The Broad Institute, Inc. | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
US12157760B2 (en) | 2018-05-23 | 2024-12-03 | The Broad Institute, Inc. | Base editors and uses thereof |
US12281338B2 (en) | 2018-10-29 | 2025-04-22 | The Broad Institute, Inc. | Nucleobase editors comprising GeoCas9 and uses thereof |
US12351837B2 (en) | 2020-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2019255789A1 (en) | 2018-04-19 | 2020-10-22 | The Regents Of The University Of California | Compositions and methods for gene editing |
US20200017865A1 (en) * | 2018-05-18 | 2020-01-16 | The Regents Of The University Of California | Methods for mitochondria and organelle genome editing |
US20240042029A1 (en) * | 2020-12-08 | 2024-02-08 | Regents Of The University Of Minnesota | Delivery of molecules to cells using trogocytosis and engineered cells |
WO2024181359A1 (en) * | 2023-02-27 | 2024-09-06 | 国立大学法人北海道大学 | Lipid nanoparticle for editing mitochondrial genome |
WO2024206687A1 (en) * | 2023-03-29 | 2024-10-03 | William Marsh Rice University | Methods and compostions for engineered mitochondrial biogenesis |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015134812A1 (en) * | 2014-03-05 | 2015-09-11 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa |
WO2015139139A1 (en) * | 2014-03-20 | 2015-09-24 | UNIVERSITé LAVAL | Crispr-based methods and products for increasing frataxin levels and uses thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8278428B2 (en) * | 2007-02-16 | 2012-10-02 | John Guy | Mitochondrial nucleic acid delivery systems |
CN106061510B (en) * | 2013-12-12 | 2020-02-14 | 布罗德研究所有限公司 | Delivery, use and therapeutic applications of CRISPR-CAS systems and compositions for genome editing |
SG11201809777VA (en) * | 2016-05-06 | 2018-12-28 | Nat Univ Singapore | Mitochondrial delivery of recombinant nucleic acids |
-
2017
- 2017-02-02 US US16/075,247 patent/US11208652B2/en active Active
- 2017-02-02 WO PCT/US2017/016168 patent/WO2017136520A1/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015134812A1 (en) * | 2014-03-05 | 2015-09-11 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa |
WO2015139139A1 (en) * | 2014-03-20 | 2015-09-24 | UNIVERSITé LAVAL | Crispr-based methods and products for increasing frataxin levels and uses thereof |
Non-Patent Citations (1)
Title |
---|
JO, A ET AL.: "Efficient Mitochondrial Genome Editing by CRISPR/Cas9", B IOMED RESEARCH INTERNATIONAL, vol. 2015, 2015, pages 1 - 10, XP055403440 * |
Cited By (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10323236B2 (en) | 2011-07-22 | 2019-06-18 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
US12006520B2 (en) | 2011-07-22 | 2024-06-11 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
US11920181B2 (en) | 2013-08-09 | 2024-03-05 | President And Fellows Of Harvard College | Nuclease profiling system |
US10508298B2 (en) | 2013-08-09 | 2019-12-17 | President And Fellows Of Harvard College | Methods for identifying a target site of a CAS9 nuclease |
US10954548B2 (en) | 2013-08-09 | 2021-03-23 | President And Fellows Of Harvard College | Nuclease profiling system |
US11046948B2 (en) | 2013-08-22 | 2021-06-29 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
US10858639B2 (en) | 2013-09-06 | 2020-12-08 | President And Fellows Of Harvard College | CAS9 variants and uses thereof |
US9999671B2 (en) | 2013-09-06 | 2018-06-19 | President And Fellows Of Harvard College | Delivery of negatively charged proteins using cationic lipids |
US11299755B2 (en) | 2013-09-06 | 2022-04-12 | President And Fellows Of Harvard College | Switchable CAS9 nucleases and uses thereof |
US10597679B2 (en) | 2013-09-06 | 2020-03-24 | President And Fellows Of Harvard College | Switchable Cas9 nucleases and uses thereof |
US10682410B2 (en) | 2013-09-06 | 2020-06-16 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
US10912833B2 (en) | 2013-09-06 | 2021-02-09 | President And Fellows Of Harvard College | Delivery of negatively charged proteins using cationic lipids |
US11124782B2 (en) | 2013-12-12 | 2021-09-21 | President And Fellows Of Harvard College | Cas variants for gene editing |
US12215365B2 (en) | 2013-12-12 | 2025-02-04 | President And Fellows Of Harvard College | Cas variants for gene editing |
US10465176B2 (en) | 2013-12-12 | 2019-11-05 | President And Fellows Of Harvard College | Cas variants for gene editing |
US11053481B2 (en) | 2013-12-12 | 2021-07-06 | President And Fellows Of Harvard College | Fusions of Cas9 domains and nucleic acid-editing domains |
US10704062B2 (en) | 2014-07-30 | 2020-07-07 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
US11578343B2 (en) | 2014-07-30 | 2023-02-14 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
US12344869B2 (en) | 2015-10-23 | 2025-07-01 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
US11214780B2 (en) | 2015-10-23 | 2022-01-04 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
US12043852B2 (en) | 2015-10-23 | 2024-07-23 | President And Fellows Of Harvard College | Evolved Cas9 proteins for gene editing |
US10167457B2 (en) | 2015-10-23 | 2019-01-01 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
US10947530B2 (en) | 2016-08-03 | 2021-03-16 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
US11702651B2 (en) | 2016-08-03 | 2023-07-18 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
US10113163B2 (en) | 2016-08-03 | 2018-10-30 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
US11999947B2 (en) | 2016-08-03 | 2024-06-04 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
US11661590B2 (en) | 2016-08-09 | 2023-05-30 | President And Fellows Of Harvard College | Programmable CAS9-recombinase fusion proteins and uses thereof |
US12084663B2 (en) | 2016-08-24 | 2024-09-10 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
US11306324B2 (en) | 2016-10-14 | 2022-04-19 | President And Fellows Of Harvard College | AAV delivery of nucleobase editors |
US11820969B2 (en) | 2016-12-23 | 2023-11-21 | President And Fellows Of Harvard College | Editing of CCR2 receptor gene to protect against HIV infection |
US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
US11542496B2 (en) | 2017-03-10 | 2023-01-03 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
US11268082B2 (en) | 2017-03-23 | 2022-03-08 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable DNA binding proteins |
US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
US11732274B2 (en) | 2017-07-28 | 2023-08-22 | President And Fellows Of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE) |
US11920140B2 (en) | 2017-08-22 | 2024-03-05 | Napigen, Inc. | Organelle genome modification using polynucleotide guided endonuclease |
CN111263810A (en) * | 2017-08-22 | 2020-06-09 | 纳匹基因公司 | Organelle genome modification using polynucleotide directed endonucleases |
AU2018320864B2 (en) * | 2017-08-22 | 2024-02-22 | Napigen, Inc. | Organelle genome modification using polynucleotide guided endonuclease |
US12173295B2 (en) | 2017-08-22 | 2024-12-24 | Napigen, Inc. | Organelle genome modification using polynucleotide guided endonuclease |
WO2019040645A1 (en) * | 2017-08-22 | 2019-02-28 | Napigen, Inc. | Organelle genome modification using polynucleotide guided endonuclease |
US11932884B2 (en) | 2017-08-30 | 2024-03-19 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
US11319532B2 (en) | 2017-08-30 | 2022-05-03 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
US11795443B2 (en) | 2017-10-16 | 2023-10-24 | The Broad Institute, Inc. | Uses of adenosine base editors |
US12157760B2 (en) | 2018-05-23 | 2024-12-03 | The Broad Institute, Inc. | Base editors and uses thereof |
US12281338B2 (en) | 2018-10-29 | 2025-04-22 | The Broad Institute, Inc. | Nucleobase editors comprising GeoCas9 and uses thereof |
WO2020159470A1 (en) * | 2019-01-28 | 2020-08-06 | Mayo Foundation For Medical Education And Research | Mitochondrial genome editing methods |
US11795452B2 (en) | 2019-03-19 | 2023-10-24 | The Broad Institute, Inc. | Methods and compositions for prime editing nucleotide sequences |
US12281303B2 (en) | 2019-03-19 | 2025-04-22 | The Broad Institute, Inc. | Methods and compositions for prime editing nucleotide sequences |
US11447770B1 (en) | 2019-03-19 | 2022-09-20 | The Broad Institute, Inc. | Methods and compositions for prime editing nucleotide sequences |
US11643652B2 (en) | 2019-03-19 | 2023-05-09 | The Broad Institute, Inc. | Methods and compositions for prime editing nucleotide sequences |
WO2021022046A1 (en) * | 2019-07-31 | 2021-02-04 | Bioskryb, Inc. | Genetic mutational analysis |
US12351837B2 (en) | 2020-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
US12031126B2 (en) | 2020-05-08 | 2024-07-09 | The Broad Institute, Inc. | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
US11912985B2 (en) | 2020-05-08 | 2024-02-27 | The Broad Institute, Inc. | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
CN112251468A (en) * | 2020-10-22 | 2021-01-22 | 钟刚 | Mitochondrial targeted gene editing complex, preparation method and application thereof, and mitochondrial genome editing method |
CN112251468B (en) * | 2020-10-22 | 2023-04-04 | 钟刚 | Mitochondrial targeted gene editing complex, preparation method and application thereof, and mitochondrial genome editing method |
Also Published As
Publication number | Publication date |
---|---|
US11208652B2 (en) | 2021-12-28 |
US20190062739A1 (en) | 2019-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11208652B2 (en) | Mitochondrial genome editing and regulation | |
US20200291370A1 (en) | Mutant Cas Proteins | |
US20190345483A1 (en) | AAV Split Cas9 Genome Editing and Transcriptional Regulation | |
EP3585159B1 (en) | Method of testing the ability of a crispr/cas9 nuclease to modify a target genomic locus in vivo, by making use of a cas-transgenic mouse or rat which comprises a cas9 expression cassette in its genome | |
US20200377881A1 (en) | Methods of Genome Engineering by Nuclease-Transposase Fusion Proteins | |
US20190380314A1 (en) | Methods of Genetic Modification of a Cell | |
US11674138B2 (en) | Methods of modulating expression of target nucleic acid sequences in a cell | |
US20220298495A1 (en) | Novel genome editing tool | |
JP2023522788A (en) | CRISPR/CAS9 therapy to correct Duchenne muscular dystrophy by targeted genomic integration | |
CN119836432A (en) | Compositions and methods for epigenetic modulation of PCSK9 expression | |
CN110891419A (en) | Evaluation of CRISPR/CAS-induced in vivo recombination with exogenous donor nucleic acids | |
US20230102342A1 (en) | Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use | |
WO2021108363A1 (en) | Crispr/cas-mediated upregulation of humanized ttr allele | |
EP4028063A1 (en) | Transcription modulation in animals using crispr/cas systems delivered by lipid nanoparticles | |
AU2022215636A1 (en) | Omni 90-99, 101, 104-110, 114, 116, 118-123, 125, 126, 128, 129, and 131-138 crispr nucleases | |
KR20240133697A (en) | A novel OMNI CRISPR nuclease | |
US20230304001A1 (en) | Methods of Modulating Expression of Target Nucleic Acid Sequences in A Cell | |
US20240216544A1 (en) | Methods and compositions for expression of editing proteins | |
CN120283052A (en) | Compositions and methods for epigenetic regulation of HBV gene expression | |
JP2025514304A (en) | Identifying tissue-specific extragenic safe harbors for gene therapy | |
WO2024229020A2 (en) | Compositions and methods for epigenetic regulation of pcsk9 expression | |
WO2023235725A2 (en) | Crispr-based therapeutics for c9orf72 repeat expansion disease | |
KR20240117571A (en) | Mutant myocilin disease model and uses thereof | |
WO2025049792A1 (en) | Compositions and methods for epigenetic regulation of tgfbr2 expression | |
WO2025030130A1 (en) | Methods and compositions comprising dnmt3a-binding antibodies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17748131 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 15.11.2018) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 17748131 Country of ref document: EP Kind code of ref document: A1 |